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ABSTRACT 
MicroRNAs (miRNAs) are small noncoding RNA molecules that have important 
regulatory roles in a wide range of biological processes. miRNAs are often expressed in 
a tissue- and/or differentiation state-specific patterns, and it is estimated that miRNAs 
can regulate the expression of more than 50% of all human genes. We have exploited 
these tissue-specific miRNA expression patterns in the modification of viral replicative 
tropism. In order to engineer the replicative tropism of oncolytic adenoviruses, we 
developed a recombinant adenovirus that in the 3’ UTR of the critical E1A gene 
contains sequences complementary to the liver-specific miRNA miR122. This allowed 
us to generate a novel recombinant adenovirus that was severely attenuated in human 
liver, but replicated to high titres in colorectal cancer. Systemic injection of miR122-
targeted adenovirus into mice did not induce liver toxicity. In a human lung cancer 
xenograft mouse model this miR122-targeted adenovirus showed potent antitumour 
activity. 
 We also studied the possibility to exploit neuron-specific miRNA expression patterns in 
the modification of tissue tropism of an alphavirus Semliki Forest virus (SFV).  We 
engineered SFV genome to contain sequences complementary to the neuron-specific 
miRNA miR124. In vitro characterization of this novel virus showed that the 
modification of the SFV genome per se did not affect polyprotein processing or 
oncolytic potency. Intraperitoneally administered miR124-targeted SFV displayed an 
attenuated spread into the central nervous system (CNS) and increased survival of 
infected mice. Also, mice pre-infected with miR124-targeted SFV elicited strong 
protective immunity against otherwise lethal challenge with a highly virulent wild-type 
SFV strain. 
In conclusion, these results show that miRNA-targeting is a potent new strategy to 
engineer viral tropism in development of safer and more efficient reagents for 
virotherapy applications. 
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1 REVIEW	OF	THE	LITERATURE	
1.1 Introduction	
MicroRNAs (miRNAs) are endogenous small, approximately 22 nucleotides long RNA 
molecules that have important regulatory roles in animals and plants. MiRNAs act as 
posttranscriptional suppressors by binding usually to the 3’untranslated region (UTR) of 
their target genes thus inhibiting their target gene expression by translation inhibition 
or messenger RNA (mRNA) degradation (Lee, Feinbaum et al. 1993; Reinhart, Slack et al. 
2000;  Lagos-Quintana,  Rauhut et  al.  2001;  Bartel  2004).  They were first  discovered in 
1993 by Lee et al. who reported that lin-4, the essential gene controlling the timing of 
C.elegans larval development does not encode for a protein but instead produces two 
small RNA transcripts of approximately 22 and 61 nucleotides in length. These two RNA 
transcripts were found to contain sequences complementary to a repeated sequence 
element in the 3’UTR of lin-14 mRNA, a gene known to be down regulated by lin-4. 
These findings led Lee et al. to propose that lin-4 regulates lin-14 translation via a novel 
antisense  RNA-sense  RNA  interaction  (Lee,  Feinbaum  et  al.  1993).  At  the  same  time  
Wightman et al. showed that the repeated sequence element in the 3’UTR of the lin-14 
gene was sufficient for its regulation and that the regulation is at the level of protein 
translation and mediated by lin-4 gene product (Wightman, Burglin et al. 1991; 
Wightman,  Ha et  al.  1993).  These findings were the first  example of  regulation of  an 
important developmental process by short RNA molecules, microRNAs. Seven years 
after  the  discovery  of  Lin-4, another essential miRNA gene controlling the timing of 
C.elegans larval development called Let-7 was identified (Reinhart,  Slack et  al.  2000).  
Soon after the discovery of let-7 in C.elegans, homologs of let-7 were identified in a 
wide range of animal species including vertebrate, ascidian, hemicordate, mollusc, 
annelid and arthropod (Pasquinelli, Reinhart et al. 2000). To date, there are over 25000 
miRNAs identified in 193 species including over 2000 miRNAs identified in the human 
genome (www.mirbase.org) (Griffiths-Jones, Saini et al. 2008). 
 
1.2 MiRNA	genes	
The majority of miRNA genes identified from C.elegans were found to be encoded by 
independent transcription units that do not contain an open reading frame and which 
are  located  quite  distant  from  previously  annotated  genes  (Lau,  Lim  et  al.  2001).  
Profiling of Drosophila melanogaster miRNA genes revealed that majority of the genes 
were in close proximity to each other forming larger gene clusters containing on 
average three different miRNA genes and the longest cluster contained eight different 
miRNA genes (Aravin, Lagos-Quintana et al. 2003). More than half of the mammalian 
miRNA genes are located within the introns of either protein-coding transcription units 
(messenger RNAs, mRNAs) or noncoding transcription units. Approximately 10% of 
miRNA genes are encoded by exons of long nonprotein-coding transcripts (mRNA-like 
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noncoding RNAs). MiRNA genes can also locate either in exon or intron depending on 
alternative splicing of the host transcript (Rodriguez, Griffiths-Jones et al. 2004). Also 
clusters of mammalian miRNA genes can overlap with a single host transcript. In those 
cases, the majority of these miRNA genes are located in the same intron or exon of the 
host transcript (Rodriguez, Griffiths-Jones et al. 2004).  
 
1.3 MiRNA	biogenesis		
1.3.1 MiRNA	transcription		
MiRNAs are transcribed as parts of longer primary transcripts (pri-miRNAs) that are 
generated by RNA polymerase II (Lee, Jeon et al. 2002; Lee, Kim et al. 2004).  Like other 
RNA polymerase II transcripts, also pri-miRNAs possess 5’ 7-methyl guanosine cap and 
a  3’  poly-A-tail.  Approximately  40  %  of  all  miRNAs  are  found  within  the  introns  of  
protein-coding genes and in these cases the spliced forms of pri-miRNAs can function 
as  mRNAs  (Cai,  Hagedorn  et  al.  2004;  Rodriguez,  Griffiths-Jones  et  al.  2004).  The  
transcribed pri-miRNAs form stem-loop structures, which contain the mature miRNA or 
miRNAs as a part of an imperfectly paired double stranded stem connected with a 
terminal loop (Lee, Ahn et al. 2003; Gregory, Yan et al. 2004).  
1.3.2 Canonical	miRNA	processing:	Pri-miRNA	processing	by	Microprocessor	
complex	
In the canonical miRNA processing pathway, the stem-loop structures are recognised 
and further processed in the nucleus by Microprocessor complex, a multiprotein 
complex including the essential components RNase III Drosha and a double-stranded- 
RNA-binding protein DGCR8 (Lee, Ahn et al. 2003; Gregory, Yan et al. 2004). Pri-miRNA 
processing consists of two sequential processing steps. First, the DGCR8 recognizes the 
single stranded RNA-double stranded RNA (ssRNA-dsRNA) junction at the root of the 
stem-loop structure and anchors the Microprocessor complex at the correct location. 
Second, Drosha transiently interacts with the substrate RNA for catalytic reaction to 
occur (Han, Lee et al. 2006). Drosha cleaves the dsRNA stem at ~11 base pair (bp) from 
the root of the stem loop-structure generating a two nucleotide (nt) overhang at the 3’ 
end (Han,  Lee et  al.  2006).  The catalytic  activity  of  Drosha results  in  a  hairpin-shaped 
dsRNA molecule of 70-100 bp in length called miRNA precursor or pre-miRNA. 
1.3.3 Noncanonical	miRNA	processing:	The	miRtron	pathway	
MiRNA processing pathways that bypass the processing by Drosha/DGCR8 are 
collectively called noncanonical miRNA processing pathways. An example of such a 
pathway is the miRtron pathway. MiRtrons are pre-miRNA hairpins located in short 
introns, characterized by the precise mapping of the mature miRNA strand and the 
complementary passenger strand, the miRNA* strand to the 5’ and 3’ ends of the 
introns (Okamura 2012). Majority of the miRtron bearing introns are sliced and the 
intron lariat is debranched to generate a pre-miRNAs that can then be exported to the 
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cytoplasm. However, a subset of these sliced and debranced miRtrons (tailed miRtrons) 
have  5’  or  3’  tails  that  require  RNA  exosome  mediated  trimming  of  the  3’  tail  or  
removal of the 5’ tail by a yet unknown mechanism for efficient export to the 
cytoplasm  (Yeo  and  Chong  2011;  Okamura  2012)  (see  figure  1.  for  schematic  
presentation of miRNA processing pathways).  
1.3.4 Nuclear	export	of	pre-miRNAs	
Pre-miRNAs processed by either canonical or noncanonical processing pathways are 
then exported to the cytoplasm by the nuclear export receptor Exportin 5 (Exp5) 
together with its cofactor Ran-guanosine triphosphate (Ran-GTP). Exp5/Ran-GTP 
complex recognize the pre-miRNA stem and the 2 nt 3’overhang generated by Drosha 
and export the complex bound pre-miRNA to the cytoplasm where the hydrolysis of 
the Ran-GTP to Ran-GDP releases the pre-miRNA for  further processing (Yi,  Qin et  al.  
2003; Bohnsack, Czaplinski et al. 2004; Lund, Guttinger et al. 2004).   
1.3.5 Pre-miRNA	processing	by	Dicer	
The cytoplasmic pre-miRNAs are further processed by a member of the RNAse III family 
of nucleases called Dicer. Dicer is a multidomain enzyme including a PAZ (PIWI, 
Argonaute and Zwille) domain, two RNaseIII domains (RNase IIIa and RNase IIIb) and a 
dsRBD (double-stranded RNA-binding) domain. The PAZ domain contributes to the pre-
miRNA substrate recognition by interacting with the two nucleotide overhang at the 3’ 
end of the pre-miRNAs and by positioning the double-stranded stem correctly for the 
cleavage.  After substrate recognition and its correct positioning by PAZ domain, the 
pre-miRNA is then cleaved  at a set distance of approximately 21-nt away from the end 
of the molecule in the catalytic centre formed by intramolecular dimerization of the 
two RNAse III domains (Bernstein, Caudy et al. 2001; Zhang, Kolb et al. 2004; Macrae, 
Zhou et al. 2006). A miRNA duplex intermediate of ~21-nt in length having 2-nt 
3’overhangs on both ends is generated as a result of Dicer processing. 
1.3.6 Dicer	independent	pre-miRNA	processing	
To  this  date,  there  is  only  one  known  example  of  Dicer  independent  miRNA,  miR451  
(Cheloufi, Dos Santos et al. 2010; Cifuentes, Xue et al. 2010). The processing of miR451 
begins with canonical processing by microprocessor complex to form pre-mirR451, but 
the subsequent processing step is unique to this miRNA. Pre-miR451 is loaded into 
Ago2  (Argonaute  2)  and  cleaved  by  the  Ago2  catalytic  centre  to  generate  an  
intermediate 3’end, which is then further trimmed by a mechanism yet unidentified 
(Cheloufi, Dos Santos et al. 2010).  
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    Figure 1. Canonical miRNA pathway, the miRtron pathway and Dicer independent pre-miRNA processing of miR451.  
 
1.4 MiRNA-induced	silencing	complex	(miRISC)	assembly		
The Dicer/miRNA intermediate complex is associated with TRBP (human 
immunodeficiency virus trans-activating response RNA-binding protein) which recruits 
the complex to Ago2 protein of the miRISC complex (Chendrimada, Gregory et al. 2005; 
Gregory,  Chendrimada  et  al.  2005).  One  strand  of  the  miRNA  duplex  (the  mature  
miRNA) is loaded into Ago2 and the other strand (miRNA*) is degraded. It has been 
shown that the miRNA duplexes are thermodynamically asymmetric and the strand 
with less  stable base pairing at  the 5’  end is  loaded into Ago2 and thus serves as  the 
mature  miRNA  (Schwarz,  Hutvagner  et  al.  2003).  Dicer  in  association  with  TRBP  can  
sense this thermodynamic asymmetry by repositioning the intermediate duplex into 
the helicase domain of Dicer where the less stable end of the duplex is bound by Dicer 
and the more stable end is bound by TRBP. This positions the 3’ end of the mature 
miRNA strand in close proximity to the Ago2 PAZ domain and finally leads to loading of 
the  RNA  duplex  into  Ago2  (Noland,  Ma  et  al.  2011).  The  N  domain  of  Ago2  then  
unwinds the duplex and removes the miRNA* strand through a slicer-independent 
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unwinding, forming core of the miRISC complex (Kwak and Tomari 2012). In addition to 
Ago2,  another  key  component  of  the  miRISC  complex  is  the  GW182  protein  family.  
Members of this family can directly interact with Ago2. In vertebrates there are three 
different GW182 paralogues named TNRC6A, -B and –C. The amino-terminal domain of 
GW182 proteins with multiple glycine-tryptophan repeats (GW-repeats) is responsible 
for Ago2 binding. In the carboxy-terminal part of the GW182 is a silencing domain (SD) 
that is an important effector domain and required for miRNA-induced repression 
(Fabian, Sonenberg et al. 2010; Huntzinger and Izaurralde 2011). Several additional 
proteins interact with miRISC complex including fragile X mental retardation protein 
(FMRP), RNA helicase RCK/p54, Importing 8 (Imp8) and TRIM32. All these proteins may 
function as regulatory factors that modulate miRNA function (Fabian, Sonenberg et al. 
2010; Huntzinger and Izaurralde 2011).  
1.5 MiRNA	target	recognition		
MiRNAs interact with their target mRNAs most commonly via base-pairing at the 3’UTR 
of mRNAs, although some miRNAs have also been shown to base-pair with regions in 
the 5’UTR of mRNAs or open reading frames (ORFs) (Duursma, Kedde et al. 2008; Orom, 
Nielsen et al. 2008). Bioinformatics as well as experimental analyses have revealed that 
the most stringent requirement for miRNA target recognition is a contiguous and 
perfect Watson-Crick base-pairing of the miRNA 5’ nucleotides 2-7, a so called seed 
region nucleating the interaction with the target mRNA, although very recent data 
suggest that a substantial fraction of miRNA target sites do not have this seed region 
base-pairing  (Lewis,  Shih  et  al.  2003;  Bartel  2009;  Khorshid,  Hausser  et  al.  2013).  In  
addition to the seed region of perfect complementarity, it has been found that A 
residue in the mRNA opposite to position 1 of the miRNA (this nucleotide does not 
need to base-pair with the miRNA nucleotides) and an additional Watson-Crick base-
pairing at position 8 improve miRNA activity (Lewis, Burge et al. 2005). Bioinformatic 
analyses have shown a lack of conservation between miRNAs and their target mRNAs 
beyond the residues immediately flanking the conserved seed region suggesting that a 
majority of miRNA-target interactions are mediated primarily by seed matches and the 
3’ portion of miRNAs has little role in target recognition. Some atypical sites with 
additional Watson-Crick base-pairing, usually centering on miRNA nucleotides 13-16,  
have also been found (Lewis, Burge et al. 2005; Bartel 2009) (see figure 2. for various 
types of miRNA target recognition). 
  
1.6 Alternative	mode	of	miRNA	target	recognition	
Recently, Chi et al. identified an alternative binding mode used by miRNAs (Chi, 
Hannon et al. 2012). By analysing the genome-wide use of atypical miRNA binding sites 
in Ago-interacting mRNAs, they found that Ago binds to a large number of bulged sites 
in vivo. This finding led them to propose a transitional nucleation model in which the 
nucleotide in position 6 of the miRNA, called the “pivot”, interacts with target bulge 
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site serving as a general means of enabling a transitional nucleation state (by stabilising 
nucleation base pairing positions 2-6), allowing subsequent bulge formation and 
propagation of the seed interaction (see figure 2. for example of alternative mode of 
miRNA target recoqnition). 
 
    Figure 2. Different types of miRNA-mRNA interactions. 
 
1.7 Mechanisms	of	gene	silencing	
After target recognition miRNAs can regulate their target gene expression through 
multiple pathways involving translational repression and/or target degradation. These 
pathways can influence each other and act synergistically, but are also capable of 
functioning independently. The contribution of an individual pathway to the overall 
degree of gene silencing might differ depending on cell type, cell condition, the context 
of target sites and the tissue level differences on the expression of critical components 
of the miRNA-machinery.  
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A  mRNA  that  is  competent  for  translation  possesses  5’  7-methyl  guanosine  cap  
structure and a 3’ poly-A-tail. The cytoplasmic poly-A-binding protein (PABPC) which is 
associated with the 3’ poly-A-tail interacts with eukaryotic initiation factor complex 4F 
(eIF4F; comprising the cap-binding protein eIF4E, an ATP-dependent RNA helicase 
eIF4A and a scaffold protein eIF4G) which in turn is associated with the 5’ cap structure 
bringing the 5’ and 3’ ends of the mRNA to a close proximity for translation initiation 
and protection from degradation (Derry, Yanagiya et al. 2006; Jackson, Hellen et al. 
2010).  
1.7.1 GW182-dependent	deadenylation	and	mRNA	destabilization	
MiRNAs  can  direct  their  target  mRNAs  to  the  cellular  5’-to  3’  mRNA  decay  pathway  
where  the  target  mRNAs  are  first  deadenylated  by  the  CRR4-NOT  or  PAN2/PAN3  
deadenylase complexes and then decapped by the decapping enzyme DCP2. This 
miRNA-mediated mRNA decay requires several components of the miRISC complex; 
The  target  recognition  is  accomplished  by  AGO  proteins  which  are  also  acting  as  a  
scaffold to recruit GW182 to the mRNA. The subsequent deadenylation is coordinated 
by GW182 that is interacting directly with the CRR4-NOT deadenylase complex 
containing the deadenylases CCR4/NOT6 and CAF1/CNOT7. GW182 can also indirectly 
interact with the PAN2/PAN3 deadenylase complex established by PABPC, an adaptor 
protein that interacts with both GW182 and PAN2/PAN3 deadenylase complex. 
The subsequent decapping involves decapping enzyme DCP2 together with several 
decapping activators including DCP1, Ge-1, EDC3 and RCK/p54 (Behm-Ansmant, 
Rehwinkel  et  al.  2006;  Wu,  Fan  et  al.  2006;  Eulalio,  Huntzinger  et  al.  2009;  Fabian,  
Mathonnet et al. 2009; Zekri, Huntzinger et al. 2009; Fukaya and Tomari 2012). The 
remaining body of the RNA is then degraded by Xrn1, a 5’-3’ exonuclease of the mRNA 
decay pathway (Fabian, Sonenberg et al. 2010). Recent studies aimed at determining 
the contribution of translational repression and mRNA degradation to the effect of 
miRNAs  on  a  genome-wide  level  suggest  that  the  predominant  mode  of  miRNA-
induced gene silencing is indeed through target mRNA destabilization (Baek, Villen et al. 
2008; Selbach, Schwanhausser et al. 2008; Hendrickson, Hogan et al. 2009; Guo, Ingolia 
et al. 2010). 
1.7.2 GW182-independent	repression	and	GW182-dependent	repression	of	early	
translation	initiation	
Gene silencing can also be induced by the miRISC-mediated inhibition of translation 
initiation by blocking the interaction of the eIF4F complex with the 5’ cap structure 
(Humphreys, Westman et al. 2005; Pillai, Bhattacharyya et al. 2005; Fukaya and Tomari 
2012). This blocking of early translation initiation step can be divided into GW182-
independent and GW182-dependent repression (Fukaya and Tomari 2012). Fukaya et 
al. showed that when knocking down GW182 protein to a level invisible in Western 
blots,  the  Ago1-RISC  complex  was  still  able  to  repress  translation  of  a  reporter  gene  
independently of GW182 and thus independently of deadenylation in Drosophila S2 
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cells.  They  also  showed  that  tethering  of  GW182  directly  to  the  reporter  mRNA  and  
simultaneously knocking down CAF1/CNOT7 of the CRR4-NOT deadenylase complex 
abolished GW182-mediated deadenylation but not translational repression. Thus, 
GW182-dependent translational repression seems to occur independently of the 
deadenylase activity of GW182. Both of these repression mechanisms block formation 
of 48S and 80S ribosomal complexes, strongly indicating that the mode of repression is 
blocking the interaction of the eIF4F complex with the 5’ cap structure (Fukaya and 
Tomari 2012). Very recently, it has been shown that also human Ago2 associates with 
the eIF4F complex via eIF4G (Ryu, Park et al. 2013). This Ago2/eIF4F association 
facilitates miRNA-mediated gene silencing, thus, possibly being the underlying 
mechanism of GW182-independent repression. 
1.7.3 Endonucleolytic	cleavage	of	mRNA	by	minimal	miRISC	complex	
There are also some reports where miRNAs have been shown to direct endonucleolytic 
cleavage of perfectly or near perfectly complementary targets (Yekta, Shih et al. 2004; 
Davis, Caiment et al. 2005). In this mode of gene silencing only minimal miRISC 
complex is required comprising Ago2 bound to the miRNA guide strand. The perfectly 
complementary target is degraded by the endonucleolytic action of Ago2 PIWI domain 
that cleaves the phosphodiester linkage between the target nucleotides that are base 
paired to the guide strand residues 10 and 11. The cleavage of the phosphodiester 
linkage generates products with 5’ -monophosphate and 3’ -hydroxyl termini that are 
further degraded by the cellular exonucleases (Hutvagner and Zamore 2002; Liu, 
Carmell et al. 2004; Carthew and Sontheimer 2009). After the initial cleavage, the 
target dissociates from the minimal miRISC complex enabling the complex to direct 
multiple rounds of target cleavage (Hutvagner and Zamore 2002). 
1.7.4 MiRNA-mediated	gene	activation	
Interestingly, miR369-3 has been shown to upregulate tumour necrosis factor α (TNFα) 
expression  in  certain  cell  conditions  (Vasudevan,  Tong  et  al.  2007;  Steitz  and  
Vasudevan 2009). TNFα mRNA contains a conserved AU-rich element (ARE) in its 3’UTR 
that exerts post-transcriptional control over the expression of TNFα. In conditions of 
cell growth arrest (upon serum starvation), TNFα translational efficiency is increased by 
the recruitment of Ago2 and fragile X mental retardation-related protein 1 (FMR1) to 
the ARE. MiR369-3 directs the association of these proteins with ARE to activate 
translation in these conditions (Vasudevan and Steitz 2007). The same miRNA was 
shown to repress translation under normal conditions, so at least some miRNAs can 
oscillate between repression and activation in coordination with the cell cycle 
(Vasudevan, Tong et al. 2008) (see figure 3 for schematic presentation of different 
mechanism of gene silencing). 
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Figure 3. Mechanisms of miRNA-mediated gene silencing and stimulation of translation. 
 
 
1.8 The	role	of	P	bodies	in	miRNA-mediated	gene	silencing	
Cytoplasmic processing bodies (P bodies) are non-membranous aggregates of 300-500 
nm in diameter that contain proteins involved in diverse posttranscriptional processes 
including mRNA storage and degradation, nonsense- mediated mRNA decay (NMD), 
translational repression of mRNAs and miRNA-mediated gene silencing (Eulalio, Behm-
Ansmant et al. 2007; Ernoult-Lange, Benard et al. 2012).  A number of findings strongly 
indicate an important role for P bodies in miRNA-mediated gene silencing. First, the 
majority of molecules involved in miRNA-mediated gene silencing have been detected 
in P bodies including all Argonaute proteins, GW182, CRR4-NOT deadenylase complex, 
DCP2-DCP1  decapping  complex  and  Xrn1  exonuclease  as  well  as  miRNAs  and  their  
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targets. Second, the inhibition of miRNA biogenesis or the depletion of GW182 proteins 
causes the disappearance of P bodies. And finally, a positive correlation occurs 
between miRNA-mediated gene silencing and the accumulation of their target mRNAs 
in P bodies (Eulalio, Behm-Ansmant et al. 2007).  Recent studies aiming at defining the 
role of P bodies in miRNA-mediated gene silencing have shown that P bodies (at least 
those microscopically visible) are not required for function, suggesting that P-body 
formation is a consequence and not the cause of miRNA-mediated gene silencing 
(Pauley, Eystathioy et al. 2006; Eulalio, Behm-Ansmant et al. 2007). 
1.9 The	regulation	of	miRNA	biogenesis			
Since a large fraction of protein-coding genes are under the regulation of miRNAs, it is 
critically important that the timing and extend of miRNA expression and their activity is 
also tightly regulated (Krol, Loedige et al. 2010; Finnegan and Pasquinelli 2012; Treiber, 
Treiber et al. 2012). The regulation can occur at each step of the miRNA biogenesis (see 
table 1). 
 
Table 1. Factors affecting the regulation of miRNA biogenesis. Adapted from (Finnegan and Pasquinelli 2012), (Treiber, Treiber 
et al. 2012) and (Hansen, Jensen et al. 2013). 
Regulation of miRNA biogenesis Factor Effect on miRNA biogenesis 
Regulation of miRNA gene transcription Transcription factors (eg. p53, PITX3) Regulation of transcription, miRNA/TF feedback loops  
Regulation of Drosha processing SMAD proteins  Stimulation of Pri-miRNA processing 
p53 Stimulation of Pri-miRNA processing 
p68/DDX Facilitation of Pri-miRNA processing 
KHSRP Stimulation of Pri-or Pre-miRNA processing 
ERα Inhibits the cleavage of specific miRNAs 
Lin-28b Repression of Let7 Pri-miRNA processing 
Regulation of Dicer processing Lin-28 Repression of Let7 Pre-miRNA processing 
TUT4 Reduction of Let7 Pre-miRNA stability 
BCRA1 Stimulation of Pre-miRNA processing 
TRBP Facilitation of Pre-miRNA processing 
PACT Facilitation of Pre-miRNA processing 
Regulation of miRISC stability Lin-48 Attenuation of miRNA-guided gene 
silencing 
Regulation of miRNA abundance circular RNAs (circRNAs) Loss of miRNA function 
 
 
1.10 MiRNA	function	
MiRNAs have a crucial role in regulating developmental morphogenesis e.g. by 
participating in the regulation of developmental timing, cell death, cell proliferation 
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and patterning of the nervous system (Bartel 2004; Shruti, Shrey et al. 2011). Here are 
examples of miRNAs that have been shown to have a key regulatory role in the control 
of organ development. 
1.10.1 MiR126	in	angiogenesis	
Angiogenic growth factors, vascular endothelial growth factor (VEGF) and fibroblast 
growth factor (FGF) modulate endothelial cell proliferation, migration and adhesion 
through activation of MAP kinase pathway, which in turn enhances the expression of 
genes required for angiogenesis and vascular integrity (Cross and Claesson-Welsh 
2001). MiR126 was found to be specifically expressed in endothelial cells and thus 
enriched in tissues with a high vascular component such as heart and lung (Wienholds, 
Kloosterman et al. 2005; Harris, Yamakuchi et al. 2008; Wang, Aurora et al. 2008). 
Using a miR126 knockout mouse model,  Wang et  al.  showed that  miR126 modulates 
angiogenesis by repressing the expression of Spred-1, a negative regulator of MAP 
kinase signalling. The miR126 knockout mice showed vascular leakage, haemorrhaging 
and embryonic lethality in a subset of mice. They concluded that miR126 functions as 
an endothelial cell-specific regulator of angiogenic signalling (Wang, Aurora et al. 2008).  
1.10.2 MiR1	in	cardiogenesis	
Several miRNA expression profiling studies have identified miR1 as a cardiac- and 
skeletal muscle specific miRNA (Lagos-Quintana, Rauhut et al. 2002; Zhao, Samal et al. 
2005; Li, Song et al. 2010). It has been shown that miR1 is a direct transcriptional target 
for several muscle differentiation regulators including serum response factor (SRF), 
MyoD, myocyte enhancer factor-2 (Mef2) (Wang 2013). MiR1 itself targets the 
transcription factor Hand2 that promotes ventricular cardiomyocyte expansion (Zhao, 
Samal  et  al.  2005).  The  expression  of  miR1  coincides  with  the  cardiac  myocyte  
differentiation and the artificial overexpression of miR1 in the developing mouse heart 
results in developmental arrest at embryonic stage E13.5, secondary to thin-walled 
ventricles and heart failure associated with reduced myocyte proliferation, thus 
demonstrating the essential role of miR1 in heart development and homeostasis (Zhao, 
Samal et al. 2005). 
1.10.3 MiR124	in	neurogenesis	
MiR124 is the most abundant miRNA of the brain, specifically expressed in neuronal 
cells in developing and adult nervous system (Lagos-Quintana, Rauhut et al. 2002; 
Smirnova, Grafe et al. 2005; Deo, Yu et al. 2006; Maiorano and Mallamaci 2009; Hua, 
Mo et al. 2012). MiR124 has been shown to have various important roles during neural 
development. The expression of miR124 mediates the repression of non-neural genes 
in neurons as well as the downregulation of genes expressed in neural progenitors (Lim, 
Lau  et  al.  2005;  Cao,  Pfaff  et  al.  2007). MiR124 promotes neuronal differentiation by 
triggering brain-specific alternative pre-mRNA splicing by suppressing the global 
repressor of alternative pre-mRNA splicing factor named polypyrimidine track binding 
protein 1 (PTBP1). In non-neuronal cells PTBP1 inhibits the alternative splicing of a 
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critical cassette exon in the pre-mRNA of polypyrimidine track binding protein 2 (PTBP2) 
exposing it to nonsense-mediated decay. In neuronal cells PTBP1 is downregulated 
resulting in an alternative splicing of pre-mRNA of PTBP2 and increase in its protein 
amount (Makeyev, Zhang et al. 2007). Also, miR124 enhances neurogenesis by 
suppressing the expression of small C-terminal domain phosphatase 1 (SCP1), a 
phosphatase that has anti-neural functions (Visvanathan, Lee et al. 2007). 
1.10.4 MiR122	in	liver	development		
MiR122 is the most abundant miRNA in the liver, accounting for more than 70% of the 
total  miRNA  population  (Lagos-Quintana,  Rauhut  et  al.  2002).  It  is  one  of  the  most  
tissue-specific miRNAs, expressed virtually exclusively in the liver (Lagos-Quintana, 
Rauhut  et  al.  2002;  Thomson,  Parker  et  al.  2004;  Landgraf,  Rusu  et  al.  2007;  Liang,  
Ridzon et  al.  2007).   Also,  the expression of  miR122 is  strongly upregulated in mouse 
liver during embryonic development. Its expression is undetectable at the earliest 
stages of liver development at embryonic stage E9.5 but is detected starting at E12.5 
reaching  to  almost  maximum  levels  at  birth  (Chang,  Nicolas  et  al.  2004).  MiR122  has  
been shown to be positively regulated by at least six different liver-enriched 
transcription factors (LETFs); hepatocyte nuclear factor (HNF) 1α, HNF3β, HNF4α, HNF6, 
Onecut2 (OC2) and CCAAT/enhancer-binding protein (C/EBP) α (Xu, He et al. 2010; Li, 
Xi et al. 2011; Laudadio, Manfroid et al. 2012). miR122 itself is shown to be involved in 
the regulation of several key regulators of development, such as transcription factors 
CUTL1 and CCCTC-binding factor (CTCF) and protein kinases MAP3K3 and MAP3K12 (Xu, 
He et al. 2010). Thus, it is suggested that miR122 functions as an effector of LETFs and 
contributes to liver development by regulating the balance between hepatocyte 
proliferation and differentiation by targeting various important developmental 
regulators (Xu, He et al. 2010).  
 
1.11 		The	role	of	miRNAs	in	cancer		
As miRNAs have emerged as key regulators of fundamental biological processes, it is 
not surprising that miRNAs can also have a profound role in pathogenesis of cancers. 
Approximately 50% of known human miRNAs  are located in fragile sites of the genome, 
that is, areas that associate with cancer, thus indicating that miRNAs might have a 
crucial function in cancer progression (Calin, Sevignani et al. 2004). In principle, miRNAs 
can function as tumour suppressors or oncogenes, but there are yet several other 
possible mechanisms through which miRNAs can affect tumourigenesis (Esquela-
Kerscher and Slack 2006; Ventura and Jacks 2009) (see table 2). The first indication of 
miRNA acting as a tumour suppressor came from the studies of Calin et al. who found 
that majority of patients diagnosed with B-cell chronic lymphocytic leukaemia (CLL) had 
deletions or downregulation of two clustered miRNA genes, miR15a and miR16-1 (Calin, 
Dumitru et al. 2002). MiR15a and miR16-1 have been shown to negatively regulate B-
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cell lymphoma 2 (BCL2), an anti-apoptotic gene that is overexpressed in many types of 
human cancers including leukaemias and lymphomas (Cimmino, Calin et al. 2005).  
Thus, the lowered or complete lack of expression of miR15a and miR16-1 in CLL results 
in increased expression of BCL2 promoting leukaemogenesis and lymphomagenesis in 
haematopoietic cells (Esquela-Kerscher and Slack 2006). 
MiR21  is  an  example  of  an  oncogene  whose  expression  is  upregulated  in  almost  all  
classes of cancer, including advanced human breast cancer, cervical cancer, ovarian 
cancer, hepatocellular cancer, esophageal cancer, head and neck cancer, pancreas 
cancer, prostate cancer, lung cancer, colon carcinoma, gliomas and B-cell lymphoma 
(Selcuklu, Donoghue et al. 2009; Jazbutyte and Thum 2010; Kumarswamy, Volkmann et 
al. 2011). MiR21 has been shown to function as an anti-apoptotic and pro-survival 
factor targeting many tumour suppressor proteins and pro-survival proteins such as 
Phosphatase and Tensin homolog (PTEN), BCL2, Programmed cell death 4 (PDCD4), 
Tropomyosin, Sprouty 1 and 2, Jagged 1 and BTG2. Deregulation of these proteins by 
miR21 overexpression can lead to development of cancer (Jazbutyte and Thum 2010).  
 
Table 2. Possible mechanism of miRNA-mediated tumourigenesis. Adapted from (Esquela-Kerscher and Slack 2006) and 
(Ventura and Jacks 2009). 
Potential oncogenic and epigenetic changes  Predicted functional consequence Examples 
Deletion of miRNA Derepression of oncogene miR-15a-16-1 
     Mutations affecting miRNA-mRNA interaction Reduced affinity for oncogene No known examples 
Increased affinity for tumour suppressor gene No known examples 
     Mutations affecting miRNA biogenesis Reduced/increased processing efficiency miR-15a-16-1 
Genomic amplification of miRNA locus Increased repression of tumour suppressor gene miR-17 -92, miR-21 
Point mutation in tumour suppressor gene Novel or increased affinity for miRNA No known examples 
Point mutation in oncogene Decreased or abolished affinity for miRNA No known examples 
Rearrangement of 3' UTR of mRNA Gain of miRNA-mediated suppression No known examples 
      Loss of miRNA-mediated repression HMGA-2 
 
 
1.11.1 MiRNAs	as	diagnostic	tools	in	cancer	classification	
Since miRNAs clearly have role in cancer development, attempts has been made to 
establish whether miRNA profiling could be used for tumour classification (Iorio and 
Croce 2012). Genome-wide profiling of miRNA expression signature (miRNome) has 
showed that different types of cancers can be identified with surprisingly high accuracy 
and the tissue of origin of poorly differentiated tumours can be identified (Lu, Getz et 
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al.  2005;  Volinia,  Calin  et  al.  2006).  In  the  first  report  aimed  at  investigating  the  
miRnome  across  large  set  of  different  cancers  (total  amount  of  samples  were  334,  
including various human cancers), Lu et al. showed by using bead-based flow 
cytometric miRNA expression profiling that tumours originating from different 
developmental lineages and differentiation states could be identified with high 
accuracy. As an example, they examined 73 bone marrow samples obtained from 
patients with acute lymphoblastic leukaemia and were able to hierarchically cluster the 
samples into three major branches: one containing all five BCR/ABL-positive samples 
and 10 out of 11 TEL/AML1 samples; a second branch containing 15 out of 19 T-cell ALL 
samples; and a third branch containing five out of six of the samples with MLL gene 
rearrangement. The authors were also able to identify with high accuracy the identity 
of poorly differentiated tumours of unknown origin by using miRNA profiling: 12 out of 
17 samples were correctly diagnosed by miRNA profiling as opposed to mRNA profiling 
of the same samples that was highly inaccurate, diagnosing correctly only one out of 17 
samples  (Lu,  Getz  et  al.  2005).  Recently,  miRNA  expression  profiling  of  11  normal  
breast tissue samples, 17 non-invasive and 152 invasive breast carcinoma samples 
obtained using Solexa deep sequencing showed that differentiation of tumour 
subtypes by miRNA expression profiling is possible, albeit the accuracy was only similar 
to that of mRNA expression profiling of the same set of samples (Farazi, Horlings et al. 
2011). 
 
1.11.2 MiRNAs	as	cancer	biomarkers	
As miRNAs can be used to distinguish tumour types and tissues were they originated 
from, can miRNA expression profiling also be used as a tool for predicting cancer 
outcome or response to therapy? First, evidence that tumour specific miRNA signature 
is associated with prognostic factors and disease progression came from miRNA 
expression  profiling  study  of  94  samples  of  CLL  cells  were  it  was  shown  that  altered  
expression signature of 13 miRNAs had clear prognostic significance and was also able 
to differentiate patients with a short interval from diagnosis to therapy from patients 
with significantly longer interval (Calin, Ferracin et al. 2005). Subsequent studies 
further established that various cancers have cancer-specific miRNA signature with 
clear prognostic value including those of breast cancer (Yanaihara, Caplen et al. 2006), 
colon adenocarcinoma (Schetter, Leung et al. 2008), malignant melanoma (Caramuta, 
Egyhazi  et  al.  2010),  gastric  cancer (Li,  Zhang et  al.  2010)  and pancreatic  cancer (Lee,  
Gusev et al. 2007). In addition to using miRNA signature to predict cancer outcome, it 
can also be used to predict patient’s response to therapy. For example, aberrant 
expression of miR21 has been linked to resistance to chemotherapeutic agents VM-26 
in glioblastoma cells (Li, Li et al. 2009), gemcitabine in pancreatic cancer (Giovannetti, 
Funel et al. 2010) and fluorourasil based agents in adenocarcinoma (Schetter, Leung et 
al. 2008). 
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1.12 MiRNAs	and	viruses	
1.12.1 Virally	encoded	miRNAs	
The first viral miRNAs were discovered in 2004 in Epstein-Barr virus (EBV), a human γ-
gammaherpesvirus belonging to the family of herpesviruses (Pfeffer, Zavolan et al. 
2004). Since then, multiple viral miRNAs have been discovered in members of all three 
herpesvirus subfamilies. From the α-herpesvirus subfamily, herpes simplex virus 1 
(HSV-1), HSV-2, Marek’s disease virus 1 (MDV-1), MDV-2, herpesvirus of turkeys (HVT) 
and infectious laryngotracheitis virus (ILTV) have been shown to express miRNAs; from 
the β-herpesvirus subfamily the human cytomegalovirus (hCMV) and mouse 
cytomegalovirus (mCMV) have been shown to express miRNAs; from the γ-herpesvirus 
subfamily Kaposi’s sarcoma-associated herpesvirus (KSHV), mouse γ-herpesvirus, 
rhesus lymphocryptovirus (rLCV), rhesus monkey rhadinovirus (RRV), EBV and murine 
herpesvirus-68 (MHV-68) have been shown to express miRNAs (Skalsky and Cullen 
2010). Although the majority of miRNAs found in viruses to date are from 
herpesviruses, some members of other DNA virus families, namely polyomavirus, 
ascovirus, baculovirus, iridovirus and adenovirus families, also express miRNAs (Cullen 
2011; Kincaid and Sullivan 2012). Apart from bovine leukaemia virus (BLV), a member 
of the Retroviridae family,  RNA  viruses  do  not  seem  to  contain  miRNAs  (Skalsky  and  
Cullen 2010; Libri, Miesen et al. 2013). Two possible explanations why RNA viruses may 
not encode miRNAs are: First, majority of RNA viruses replicate in the cytoplasm and 
thus cannot access the host nuclear factors such as Drosha and DGCR8 required for 
miRNA biogenesis as opposite to miRNA-expressing double-stranded DNA viruses that 
replicate in the host nucleus. Second, processing of miRNAs from nuclear RNA viruses 
such as human immunodeficiency virus 1 (HIV-1) would mean the cleavage and 
degradation of the viral genomic RNA (Skalsky and Cullen 2010). A recently found 
exception of these rules is the bovine leukaemia virus, a retrovirus that replicates in 
the nucleus and has been shown to express 10 noncanonical RNA-polymerase III 
transcribed miRNAs (Kincaid, Burke et al. 2012; Rosewick, Momont et al. 2013). Since 
the noncanonical processing of these miRNAs does not involve Drosha or DGCR8, the 
viral RNA genome and viral mRNAs transcribed by RNA polymerase III escape cleavage 
and degradation involved in canonical miRNA biogenesis (Kincaid, Burke et al. 2012). 
1.12.2 Functions	of	virally	encoded	miRNAs	
Viral miRNAs can target both host mRNAs and viral mRNAs and are involved, together 
with other viral factors, in cellular reprogramming including: i) regulation of the latent-
lytic switch of infection ii) modulation of immune responses iii) supporting viral 
replication by promoting cell survival, proliferation and/or differentiation (Skalsky and 
Cullen 2010; Takane and Kanai 2011). For example, infectious laryngotracheitis virus 
miRNA iltv-miR-I5 has been shown to participate in the regulation of latency by 
targeting the major transcriptional regulator ICP4 gene that is essential for viral growth 
and is repressed during latency (Waidner, Burnside et al. 2011). The iltv-miR-I5 lies 
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antisense  to  and  is  100%  complementary  to  its  target  ICP4  and  regulates  the  ICP4  
mRNA expression by direct endonucleolytic cleavage (Waidner, Burnside et al. 2011). 
Similar miRNA-driven regulation of the latent-lytic switch of infection has been also 
shown in other herpesviruses;  EBV miR-BART2 regulates viral  DNA polymerase BALF4 
expression inhibiting the transition from latent to lytic infection (Barth, Pfuhl et al. 
2008) and HSV-1 miR-H2-3p and miR-H6 regulate viral immediate early transcription 
activator ICP0 and HSV-1 ICP4, respectively, stabilizing viral latency (Umbach, Kramer et 
al. 2008). Viral miRNAs can also affect host gene expression in order to modulate the 
host cell environment into one more suitable for virus replication. For example, KSHV 
encodes four miRNAs that are strong suppressors of a particular host gene, 
thrombospondin 1 (THBS1) (Samols, Skalsky et al. 2007). THBS1 is a potent tumour 
suppressor gene and anti-angiogenic factor that functions via activating the latent form 
of transforming growth factor β (TGF-β). Thus, KSHV-encoded miRNAs contribute to 
the pathogenesis by decreasing TGF-β activity via down-regulation of THBS1 (Samols, 
Skalsky  et  al.  2007).  KSHV  also  encodes  an  ortholog  of  human  miR155,  a  critically  
important regulator in B-cell development and an oncogene which expression is 
frequently found to be up-regulated in lymphomas (Skalsky, Samols et al. 2007). KSHV-
miR-K12-11 shares 100% seed sequence with human miR155 and they regulate 
common  set  of  cellular  mRNAs.  It  is  thought  that  sustained  KSHV-miR-K12-11  
expression  in  KSHV  infected  B-cells  regulates  a  set  of  miR155  targets  in  a  
developmental stage where miR155 is not normally expressed and thereby directly 
contributes to deregulated non-mature B-cell proliferation, potentially leading to 
lymphomagenesis (Skalsky, Samols et al. 2007). 
1.12.3 Interplay	between	host	cell-encoded	miRNAs	and	viruses	
Cellular miRNA expression is profoundly altered upon viral infection due to the 
alteration of cellular environment by viral factors as well as host antiviral defences 
(Skalsky and Cullen 2010). Cellular miRNAs have been shown to promote viral 
replication, also, viral factors have been shown to suppress individual cellular miRNAs 
as well as to suppress the global miRNA biogenesis, thereby indicating intricate 
interplay between cellular miRNAs and viral factors affecting replication (Cullen 2011). 
The first direct interaction among cellular miRNA and virus genome was identified 
between hepatitis C virus (HCV) and liver-specific miR122 (Jopling, Yi et al. 2005). HCV 
replication was shown to be dependent of miR122 expression and upon inhibition 
miR122 by 2’-O-methylated RNA oligonucleotide with exact complementarity to 
miR122 HCV replication was reduced drastically (Jopling, Yi et al. 2005). Several viruses, 
including  KSHV  and  mCMV,  as  well  as  HIV-1,  have  been  shown  to  up-regulate  host  
cellular  miR132  upon  infection  (Lagos,  Pollara  et  al.  2010;  Chiang,  Liu  et  al.  2013).  
MiR132 targets transcriptional coactivator p300 and also a transcriptional regulatory 
protein methyl-CpG binding protein 2 (MeCP2) that in turn inhibits the expression of a 
number of interferon-stimulated genes, thereby resulting in enhanced replication of 
these viruses (Lagos, Pollara et al. 2010; Chiang, Liu et al. 2013). Adenoviruses encode a 
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noncoding RNA called VA1, a 160 nucleotide long structured RNA that is expressed at 
extremely high levels (approximately 108 molecules/cell) during adenoviral replication 
(Mathews and Shenk 1991). The high level expression of VA1 in infected cells 
negatively affects the nuclear export of host pri-miRNAs by Exp5. VA1 can bind to Exp5 
and inhibit pre-miRNA export possibly by outcompeting the host pre-miRNAs for Exp5 
binding, thus downregulating the production of mature miRNAs (Lu and Cullen 2004). 
Human papillomavirus (HPV) can modulate expression of host miR203 and thus 
allowing viral replication to occur in differentiated epithelial cells (Melar-New and 
Laimins 2010). The HPV life cycle is closely associated with the differentiation program 
of skin epithelial cells; HPV establishes a latent infection in skin epithelial cells, but 
when these infected cells begin to differentiate into suprabasal cells, the late promoter 
of HPV is activated resulting in DNA amplification, late gene expression and start of the 
productive phase of the life viral cycle. Normally these differentiated suprabasal cells 
undergo  cell  cycle  arrest  mediated  in  part  via  the  repression  of  p63  family  of  
transcription factors by the host miR203, but when infected with HPV, viral E6 and E7 
oncoproteins block the cell cycle arrest by downregulating miR203 expression, thus 
allowing differentiated cells to remain in the active state and enabling productive 
replication  to  occur  (McKenna,  McDade  et  al.  2010;  Melar-New  and  Laimins  2010;  
Mighty and Laimins 2011). 
 
1.13 Rational	exploitation	of	miRNA	machinery	
1.13.1 MiRNA-regulated	lentiviral	vectors	for	gene	therapy	
The first report of exploiting miRNA-machinery for the regulation of a transgene came 
from the laboratory of Luigi Naldini. They showed that endogenous miRNAs could be 
used to specifically suppress transgene expression from lentiviral vectors in 
haematopoietic lineages and maintain expression in non-haematopoietic cells (Brown, 
Venneri et al. 2006). A major barrier to successful gene therapy has been the 
development of transgene-specific immunity where transgene expressing professional 
antigen-presenting cells (APCs) induce immune responses against the transgene. The 
hypothesis behind the first targeting experiment done in Naldini’s laboratory was that 
by targeting the transgene to haematopoietic-specific miRNA could they prevent the 
transgene expression in haematopoietic lineages (including APCs) and thus, the 
induction of the immune responses against the transgene could be avoided enabling 
stable gene transfer. To test the hypothesis, they constructed a miRNA-regulated 
lentiviral vector by inserting four tandem copies of a sequence perfectly 
complementary to a haematopoietic-specific miRNA miR-142 in the 3’ untranslated 
region (3’UTR) of green fluorescent protein (GFP).  By developing transgenic mice using 
this novel virus they showed that the transgene expression was virtually undetectable 
in all haematopoietic cell lineages but detectable in non-haematopoietic cells. This 
virus was then systemically administered to immunocompetent mice and was shown to 
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enable stable gene transfer indicating that by using this novel miRNA-regulated 
lentiviral vector, high-level and stable expression of a transgene can be successfully 
established in an immunocompetent mice (Brown, Venneri et al. 2006). To further 
examine the efficacy of miRNA-regulated lentiviral vectors in a more relevant 
preclinical model of gene therapy, the same group showed that by using a 
haematopoietic-specific miR-142 targeted lentiviral vector expressing clotting factor IX 
(FIX) for the treatment of haemophilia B, it was possible obtain stable correction of the 
disease (Brown, Cantore et al. 2007). More recently, Matsui et al. showed that miR-142 
targeted lentiviral vector pseudotyped with baculovirus GP64 envelope glycoprotein 
expressing clotting factor VIII (FVIII) was able to mediate stable transgene expression in 
haemophilia A mice systemically treated with the virus (Matsui, Hegadorn et al. 2011). 
Gentner et al. developed a miR126-regulated lentiviral vector where the expression of 
the transgene galactocerebrosidase was restricted in haematopoietic stem cells but 
robustly expressed in mature haematopoietic cells, thus allowing successful treatment 
of globoid cell leukodystrophy (Gentner, Visigalli et al. 2010). Apart from de-targeting 
the transgene expression from the cells of haematopoietic origin, neuronally expressed 
miRNA has also been exploited for selective lentiviral transgene expression. Colin et al. 
used neuron-specific miR124 to de-target transgene expression away from neuronal 
cells towards more restricted expression in astroglial cell populations of the mouse 
brain (Colin, Faideau et al. 2009). 
1.13.2 MiRNA-targeted	non-replicating	virus	vectors,	virus-like	replicon	particles	
and	viral	amplicons	
The first report using miRNA-targeted non-replicating virus vector originated from the 
laboratory of Hiroyuki Mizuguchi where they used non-replicating adenovirus (Ad) 
vector regulated by the liver-specific miR122 to de-target suicide gene expression from 
the liver (Suzuki, Sakurai et al. 2008). They showed that by combining intratumourally 
administered Ad vector expressing HSV thymidine kinase (Ad-HSVtk) and concomitant 
ganciclovir administration as a therapeutic strategy for cancer gene therapy, the 
growth of established tumours in mice could be dramatically suppressed. However, 
intratumourally injected Ad-HSVtk disseminated into the systemic circulation and 
efficiently transduced liver giving rise to HSVtk expression in the liver leading to severe 
hepatotoxicity following ganciclovir administration. By introducing four tandem copies 
for  the  liver-specific  miR122  into  the  3’UTR  of  the  HSVtk  expression  cassette,  the  
residual HSVtk expression in the liver was dramatically reduced following 
intratumourally administered miR122-targeted Ad-HSVtk without altering the 
antitumour effects (Suzuki, Sakurai et al. 2008). By using similar miR122-based 
targeting strategy, Geisler et al. developed miR122-regulated adeno-associated virus 
(AAV9) to decrease unwanted liver transgene expression upon cardiac gene transfer 
(Geisler, Jungmann et al. 2011). Xie et al. further improved the tissue tropism of AAV9 
by inserting targets for another highly expressed and tissue-specific miRNA miR1 
together  with  miR122.  This  miR1  and  miR122-regulated  virus  was  shown  to  have  
29 
 
restricted transgene expression in liver as well as in heart and skeletal muscles allowing 
more specific expression in the central nervous system (CNS) (Xie, Xie et al. 2011).  
MiRNA-targeting has recently been exploited also in the production scheme of virus-
like particles (VRP) for Venezuelan equine encephalitis virus (VEEV) vaccine 
development. Kamrud et al. introduced miRNA target elements for ubiquitously 
expressed miRNAs into the helper RNAs that provide the alphavirus structural proteins 
needed in the production of VRPs (Kamrud, Coffield et al. 2010). Since the expression 
of structural proteins from the helper RNAs is not intented to occur in any cells other 
than those used to produce VRPs, the targeting of helper RNAs with miRNAs that are 
evolutionary conserved and ubiquitous leads to the degradation of the targeted helper 
RNAs  in  a  wide  range  of  cell  types.  This  miRNA-targeting  of  helper  RNAs  builds  an  
additional barrier to reconstruction of a functional genome by making any recombinant 
RNA (as result of a potential recombination event between helper RNAs and replicon 
RNA) susceptible to miRNA-mediated RNA degradation present in host cells. Lee et al. 
developed miRNA-regulated helper virus-depended HSV-1-based treatment strategy 
for prostate cancer (Lee, Rennie et al. 2009). They created ICP4-expression amplicons 
that  contained  target  elements  for  miR143  and  miR145  in  the  3’UTR  of  ICP4.  The  
miRNAs  miR143  and  miR145  are  expressed  in  normal  tissues  but  downregulated  in  
many types of cancer cells including prostate cancer. These amplicons can complement 
the replication of ICP4- helper virus when present in the same cell. By using this miRNA-
targeted amplicon/helper-virus system in human prostate cancer xenograft mouse 
model, they showed increased tumour specificity and potent suppression of tumour 
growth as compared to non-targeted amplicon/helper-virus system. 
1.13.3 MiRNA-targeted	replication	competent	viruses		
1.13.3.1 MiRNA-targeted	oncolytic	viruses	
Oncolytic viruses have been designed to replicate preferentially in tumour cells leaving 
normal cells unharmed. However, significant toxicity and residual replication in normal 
tissues can still occur, often limiting their application. Since the discovery that miRNAs 
can potently suppress foreign genes, attempts have been made to exploit miRNA 
machinery in order to modify viral tropism of replication. The first reported oncolytic 
virus that was engineered to exploit miRNA machinery was vesicular stomatitis virus 
(VSV), a negative-sense RNA Rhabdovirus. Edge et al. incorporated three perfectly 
complementary  target  elements  for  miRNA  Let7a  into  the  3’UTR  of  VSV  matrix  (M)  
gene. Let7a is ubiquitously expressed in normal tissues but has reduced expression in a 
wide variety of tumours. M protein has an essential role in VSV growth and replication, 
and it also serves to counteract antiviral responses (Edge, Falls et al. 2008). Edge et al. 
showed that this Let7a-targeted VSV, VSVlet-7wt, had reduced pathogenicity but retained 
potent antitumour activity in both immune competent and immunodeficient mice 
models.  
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Hikichi et al. also exploited Let7a to control the replication specificity of vaccinia virus, 
a  double-stranded DNA virus of  the Poxvirus family  (Hikichi,  Kidokoro et  al.  2011).  By 
inserting  four  target  elements  for  Let7a  into  the  3’UTR  of  B5R gene, the product of 
which is essential for robust viral replication in tumours, they were able to develop a 
highly attenuated oncolytic vaccinia virus that selectively replicated in tumour cells 
without affecting normal cells. Let7a-targeting has also been used to control the 
replication specificity of oncolytic adenoviruses. Jin et al. inserted eight target elements 
for Let7a into the 3’UTR of E1A, a key gene associated with adenoviral replication (Jin, 
Lv et al. 2011). In that study, it was found that Let7a expression was significantly 
downregulated in a proportion of primary hepatocellular carcinoma (HCC) tissues as 
compared to the Let7a expression in normal liver. Based on those findings, SG7011let7T, 
an oncolytic recombinant Ad5 adenovirus containing target elements for Let7a was 
developed for the treatment of HCC. In vitro characterization of SG7011let7T showed 
that in cell lines resembling normal liver cells (expressing high levels of Let7a) the 
replication of SG7011let7T was more than 300-fold reduced as compared to that of the 
wild-type adenovirus 5, whereas in HCC cell lines the replication was similar with both 
viruses. In vivo characterization of SG7011let7T revealed that the oncolytic potency was 
comparable to the wild-type adenovirus 5 in mice with xenograft tumours expressing 
reduced levels of Let7a.  
In another study aiming at developing an oncolytic virus for the treatment of HCC, Fu et 
al.  constructed  an  oncolytic  Herpes  Simplex  virus  (HSV),  a  DNA  virus  of  the  family  
Herpesviridae,  that  precisely  targets  HCC cells  via  the combined use of  a  strong liver-
specific promoter and miRNA-mediated de-targeting (Fu, Rivera et al. 2012). This HCC 
targeted oncolytic HSV was constructed by linking the essential viral glycoprotein H 
gene with the liver-specific apolipoprotein E (apoE)-AAT promoter and by adding target 
elements for the liver-specific miRNA miR122 together with the neuron-specific miRNA 
miR124 and Let7a into the 3’UTR of the H gene. The resulting virus, called liver-cancer 
specific oncolytic virus (LCSOV), was shown to have selective replication tropism 
towards  HCC  cells  that  do  not  express  miR122  and  was  also  shown  to  leave  normal  
hepatocytes unharmed. Indeed, liver-specific miRNA miR122 has been widely exploited 
to de-target the viral replication from the liver. This approach has been used especially 
for developing safer oncolytic adenoviruses, which is a central topic of this study (see 
later). Other authors who have been active in this field include Cawood et al., who 
could show that systemically administered miR122-targeted adenovirus 5 was 
dramatically less hepatotoxic as compared to wild-type adenovirus 5 when injected 
into mice. They further showed that the miR122-targeted virus had a potent anti-
cancer activity in a mouse HepG2 xenograft model (Cawood, Chen et al. 2009; Cawood, 
Wong et al. 2011). Leja et al. combined the use of miR122 with the neuroendocrine-
selective CgA promoter to drive the expression of E1A in order to further improve the 
selective replication of the miR122-targeted virus for the treatment of liver metastases 
(Leja, Nilsson et al. 2010). They showed that the replication specificity was enhanced 
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towards carcinoid cells and that the replication in liver was further reduced by 
combining miR122-targeting with the CgA promoter driving E1A expression. Sugio et al. 
combined human telomerase reverse transcriptase promoter driving E1-expression 
cassette and the incorporation of different combination of target elements for miR122 
and for miRNAs that are ubiquitously expressed in normal cells (Sugio, Sakurai et al. 
2011). The in vitro characterization of these different miRNA-targeted viruses showed 
significantly improved safety profiles as compared to the telomerase reverse 
transcriptase promoter-modified virus. Importantly, tumour cell lysis activity was 
shown to be unaltered. 
The tropism of otherwise neurovirulent or neurotoxic viruses has also been successfully 
modified by the use of neuronally expressed miRNAs. Kelly et al. exploited the neuron-
specific miRNA miR125b for the attenuation of VSV neuropathogenicity by 
incorporating four target elements for miR125b into the 3’UTR of the viral polymerase 
(L) gene (Kelly, Nace et al. 2010). They showed that intracranially administered miR125-
targeted VSV had reduced neurotoxicity as compared to a control virus but retained its 
antitumour  activity  in  a  mouse  CT-26  colorectal  cancer  model.  Leber  et  al.  used  
neuron-specific miR7, which is downregulated in gliomas but highly expressed in 
normal brain tissue, for the miRNA-targeting of an oncolytic measles virus (MV), a 
negative-stranded RNA virus of the family Paramyxoviridae (Leber, Bossow et al. 2011). 
By using a mouse strain highly susceptible for MV infection (CD46Ge Ifnarko) they 
showed that the neuropathogenicity of MV could be completely abrogated by the 
insertion of  3 target  elements for  miR7 into the 3’UTR of  the viral  fusion (F) gene. In 
addition, by using a mouse U87 glioblastoma xenograft model, they showed that the 
oncolytic potency of the miR7-targeted MV was fully retained. 
Finally, muscle-specific miRNAs have also been used to decrease virus pathogenicity. 
Kelly  et  al.  showed  that  the  lethal  myotropism  of  Coxsackievirus  A21  (CVA21,  a  
positive-strand RNA virus of the family Picornaviridae) could be prevented by the 
addition of miRNA target elements for two muscle-specific miRNAs, miR206 and 
miR133, into the 3’UTR of the viral genome (Kelly, Hadac et al. 2008). They showed in 
mice that CVA21 is a potent oncolytic virus mediating rapid regression of large tumours 
over a short time span, which, unfortunately, is followed by severe and progressive 
muscle paralysis within 12 days of virus infection. However, this myositis could be 
prevented by the use of muscle-specific miRNA-targeted CVA21 (miRT CVA21). Tumour 
bearing mice treated with miRT CVA21 showed significantly increased survival as 
compared to the group of mice treated with CVA21 while retaining its potent 
antitumour activity. 
1.13.3.2 MiRNA-targeted	viruses	for	vaccine	development	
Live attenuated virus vaccines are an effective method of immunisation since viral 
replication elicits strong immune response activating all the components of the 
immune system. MiRNAs can be exploited in the rational engineering of attenuated 
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virus vaccines. Indeed, the very first example of miRNA-targeted replication competent 
virus came from the vaccine studies by the laboratory of Raul Andino, as they showed 
that poliovirus (a positive-strand RNA virus of the family Picornaviridae) replication can 
be attenuated by the use of Let7a target element inserted into the viral genome (Gitlin, 
Stone et al. 2005). In a subsequent study they showed that poliovirus replication in the 
mouse brain can be specifically attenuated by incorporating miRNA target elements for 
miR124 into the poliovirus genome (Barnes, Kunitomi et al. 2008). This miR124-
targeted poliovirus (PV-124) replicated robustly in non-neuronal tissues, but was 
suppressed in the CNS leading to attenuated neuropathogenicity in the infected mice. 
Infection with PV-124 induced comparable neutralizing antibody titres to those 
observed for the Sabin-vaccine strain and immunized mice were protected against 
lethal challenges of pathogenic wild-type virus. Perez et al. developed a miRNA-
mediated complementary attenuation strategy for influenza A virus (segmented 
negative-strand RNA virus of the family Orthomyxoviridae) to increase attenuation and 
improve  vaccine  safety  (Perez,  Pham  et  al.  2009).  By  incorporating  miRNA  target  
elements for miR93, which is expressed ubiquitously in both human and mouse lung 
tissues but not in chicken, into the open-reading frame of the viral nucleoprotein, they 
generated life attenuated influenza vaccines that were attenuated in mice but not in 
the chicken eggs they were produced in.  
 
1.14 	Adenovirus	5	biology	
Adenovirus virion is a nonenveloped icosahedral particle of 70-90 nm in size with an 
outer capsid surrounding an inner nucleoprotein core. The capsid is consisting of three 
major proteins; hexon, penton base and a knobbed fibre and four associating minor 
proteins; VI, VIII, IX, and IIIa. Six other structural components are situated in the virus 
nucleoprotein core V, VII, Mu, Iva2, Terminal protein TP and 23K virion protease. From 
these proteins,  V,  VII,  Mu,  Iva2 and TP are associated with the double-stranded DNA 
genome. The linear DNA is approximately 36 kilobases long and contains inverted 
terminal  repeats  (IVR)  at  both  ends  to  which  the  terminal  protein  TP  is  covalently  
linked. Genes are encoded on both strands of the DNA with overlapping transcription 
units (McConnell and Imperiale 2004; Russell 2009).  
Adenovirus 5 initial attachment to the cell surface occurs through binding of the fiber 
knob to the cocsackievirus B and adenovirus receptor (CAR) that is expressed 
ubiquitously in various human tissues including liver, heart, lung and brain (Meier and 
Greber 2004). CAR, a type 1 transmembrane protein of the immunoglobulin 
superfamily, functions normally as a cell-to-cell adhesion molecule on tight junctions 
and basolateral surface of epithelial cells. After binding to the CAR receptor, an 
exposed RGD motif on the penton base interacts with αvβ3 or αvβ5 integrin receptors 
triggering the virus internalization by chlatrin-dependent, receptor mediated 
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endocytosis (McConnell and Imperiale 2004). The acidic pH of the endosomes triggers 
virus to penetrate into the cytosol and allows the virus to engage microtubule-
associated motors for movements towards the nuclear envelope for docking at the 
cytosolic  side  of  the  nuclear  pore  complex  (NPC)  (Greber,  Willetts  et  al.  1993;  
Suomalainen and Greber 2013). Disassembly of the capsid at the NPC allows for 
nuclear entry of the viral genome and subsequent start of the viral transcriptional 
program (McConnell and Imperiale 2004). The first viral transcription unit that is 
expressed upon infection is E1A. Transcription of E1A leads to multiple mRNA and 
protein isoforms through differential mRNA processing. Two E1A protein species are 
produced during early infection: 289R and 243R proteins. These proteins transactivate 
the other early transcription units E1B, E2, E3 and E4 and induce the host cell to enter 
the S-phase for optimal virus replication (McConnell and Imperiale 2004). The main 
mechanism  by  which  E1A  forces  host  cell  to  enter  S-phase  is  the  ability  of  289R  and  
243R to sequester hypophosphorylated pRb that is in complex with transcription 
factors of the E2F family. The binding of E1A to the pRb releases these transcription 
factors (E2F and DP) resulting in a stimulation of E2F-dependent transcription and 
entry into S-phase (Frisch and Mymryk 2002). The E1B transcription unit produces two 
proteins: E1B-55K and E1B-19K. E1B-55K acts to block p53-dependent apoptosis by 
directly binding to p53 and abrogating its ability to induce expression of proapoptotic 
genes. E1B-19K is involved in prolonging cell survival by interacting and ablating the 
members of the proapoptotic Bax family proteins. The E2 transcription unit produces 
three proteins: 72 kDa single stranded DNA-binding protein, preterminal protein and 
DNA polymerase. These proteins are necessary for the replication of the viral genome. 
The E3 transcription unit produces at least seven different proteins: Adenovirus death 
protein (ADP), E3-6.7K, E3-12.5K, E3-gp19K, E3-10.4K, E3-14.5K and E3-14.7K. The E3-
gp19K is localised in the endoplasmic reticulum (ER) membrane and prevents the 
translocation of MHC class I heavy chain to the cell surface. The E3-10.4K, E2-14.5K and 
E3-14.7K have been shown to inhibit the induction of apoptosis by various chemokines. 
ADP is required for efficient virus release (Russell 2000; Lichtenstein, Toth et al. 2004; 
McConnell and Imperiale 2004). The E4 transcription unit produces 7 proteins: E4orf1, 
E4orf2, E4orf3, E4orf3/4, E4orf4, E4orf6 and E4orf6/7. These proteins mainly facilitate 
viral mRNA metabolism, promote DNA synthesis and shut-off of host protein synthesis 
(Weitzman  2005).  The  expression  of  early  genes  modulates  the  host  cell  to  facilitate  
the genome replication and resultant transcription and translation of the late genes. 
The late genes are transcribed from the major late promoter (MLP)  that produces a 28 
kb-long nuclear RNA precursor which is processed into at least 16 different mRNAs that 
can  be  arranged  into  five  3'-coterminal  families,  L1-L5  (Le  Moullec,  Akusjarvi  et  al.  
1983). These mRNAs encode the structural components and other proteins involved in 
virion assembly (Russell 2000). 
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1.14.1 Adenoviral	vectors	in	cancer	virotherapy	
Adenoviruses have gained a great deal of interest as cancer therapeutics because they 
can be easily manipulated and exhibit oncolytic properties that can be expanded 
throughout the tumour mass by viral replication and following spread of the progeny 
viruses (Choi, Lee et al. 2012).  Multiple different strategies have been used to develop 
tissue restricted and more potent oncolytic adenoviruses. ONYX-015, the first oncolytic 
adenovirus used to treat human cancers, was generated by deleting E1B-55K gene that 
rendered the replication slightly more towards p53-deficient cancer cells (Heise, 
Sampson-Johannes  et  al.  1997;  Kirn,  Hermiston  et  al.  1998).  Control  of  viral  gene  
expression by tissue-specific or tumour-specific promoters (TSPs) has also been 
exploited. Since E1A is the first gene to be transcribed after infection and essential for 
viral replication, control of E1A expression by TSPs has been widely used (Choi, Lee et 
al. 2012). Mutation of E1A by ablating its affinity towards pRb (E1A-∆24) renders viral 
replication towards cells with transformed phenotype (e.g tumour cells) (Stolarek, 
Gomez-Manzano et al. 2004). Transductional targeting has also been exploited to 
increase infection towards tumour cells or decrease infectivity towards normal cells. 
Ad5 fibre (which binds to the CAR receptor often modestly expressed in the surface of 
tumour cells) has been changed to fibres of various other serotypes in order to 
enhance transduction of tumour cells and to ablate the dependency of the CAR 
receptor for virus entry (Ranki and Hemminki 2010). Selected modifications used in 
clinical trials are shown in table 3. 
 
Table 3. Modifications of adenoviruses used in the clinics. 
Virus  Modification Effect Reference 
Adenovirus E1A-∆24 
Replicates in cells with downregulated pRb 
function or abnormal cell cycle control 
mechanisms 
(Stolarek, 
Gomez-
Manzano et 
al. 2004) 
∆ E1B-55k Resticted replication towards tumour cells 
(Heise, 
Sampson-
Johannes et 
al. 1997) 
hTERT promoter driving E1A 
and E1B expression 
Resticted replication towards telomerase 
expressing cells → tumour cells 
(Kawashima, 
Kagawa et 
al. 2004) 
PPT artificial promoter 
driving E1A expression 
Prostate-specific E1A expression and viral 
replication 
(Cheng, 
Dzojic et al. 
2006) 
Ad5 with serotype 3 knob 
Targeting adenovirus 5 to the serotype 3 receptor 
→ increased tumour targeƟng 
(Kanerva, 
Mikheeva et 
al. 2002) 
GM-CSF gene Enhances immune responses towards cancer cells 
(Koski, 
Kangasniemi 
et al. 2010) 
  
bispecific adapter 
sCARhMFE 
Targeting transduction towards CEA-expressing 
tumours 
(Li, Everts et 
al. 2009) 
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1.15 	Semliki	Forest	virus	biology	
Semliki Forest virus (SFV) virion is an enveloped icosahedral particle of 65-70nm in size. 
The genome is composed of a single-strand positive-sense RNA genome approximately 
11.5 kb in length. The viral RNA encodes four non-structural proteins (nsp1-4) involved 
in virus replication and five structural proteins (E1, E2, E3, 6K and capsid) that compose 
the virion. The viral RNA is encapsidated by the capsid proteins forming a nucleocapsid 
(NC) that in turn is enveloped in host-derived lipid bilayer membrane on which the viral 
glycoproteins are situated (Jose, Snyder et al. 2009).  
SFV enters the host cell via clathrin-mediated endocytosis (Helenius, Kartenbeck et al. 
1980; Helenius, Kielian et al. 1985). Both E2 and E1 spike glycoproteins are involved in 
the entry: binding to the host receptor induces conformational changes in E2 and E1 
proteins and the virion is subsequently endocytosed into the cell (Kielian and Helenius 
1985).  Inside  the  cell  the  virion  is  in  a  vesicle  called  endosome.  As  the  endosome  
matures to late endosome, it becomes more acidic leading to the destabilization of E2-
E1 complex and subsequent exposure of a fusion loop at the tip of the E1 protein. This 
fusion peptide is inserted into the late endosomal membrane leading to the 
disassembly of viral spikes and the formation of E1 homotrimers (Li, Jose et al. 2010). 
This causes the fusion of viral envelope with the late endosomal membrane allowing 
the virus capsid to be released into the cytoplasm. In the cytoplasm the unenveloped 
capsid is disassembled and viral RNA is released (Wengler, Koschinski et al. 2003). 
Three different RNA species is produced from the released viral RNA: positive-strand 
viral genomic RNA, negative-strand RNA and subgenomic RNA that is used for 
translation of the structural proteins (Salonen, Ahola et al. 2005). The non-structural 
proteins are initially translated from the viral RNA as a single polypeptide P1234. This 
polypeptide is then processed by a protease domain in the nsp2 into mature nsp-
proteins as well as cleavage intermediates that have specific functions in virus 
replication. Nsp4 and the cleavage intermediate P123 produces negative-strand RNA as 
a first RNA species produced during the infection (Jose, Snyder et al. 2009). As the 
infection proceeds, the negative-strand RNA production decreases as the continuous 
nsp2 processing cleaves the intermediates to mature nsp1-3 proteins. The fully 
matured nsp1-4 proteins form the late replicase that efficiently produces both full 
length genomic RNA and the subgenomic RNA for the production of structural proteins: 
capsid  (C),  E3,  E2,  6K  and  E1  (Leung,  Ng  et  al.  2011).  The  cleavage  of  the  structural  
polypeptide occurs cotranslationally and begins with the autoproteolytic cleavage of 
the capsid protein from the remaining polypeptide. As capsid proteins begin to 
associate  with  the  newly  synthesised  genomic  RNA,  the  N-terminus  of  p62,  the  
precursor  of  the  E3  and  E2  proteins,  acts  as  a  signal  sequence  for  insertion  of  the  
polypeptide into the endoplasmic reticulum (ER) where it hetero-oligomerizes with E1. 
p62 is processed into E3 and E2 by a host furin-like protease late during the transport 
in the secretory pathway. Finally the matured E1 and E2 glycoproteins are transported 
to the cell surface via the secretory route (Melancon and Garoff 1987; Leung, Ng et al. 
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2011). The genomic RNA containing nucleocapsids assembled in the cytoplasm move to 
the plasma membrane where they interact with membrane bound viral glycoproteins 
and acquire the lipid bilayer during budding of the virions (Strauss and Strauss 1994). 
1.15.1 Semliki	Forest	virus	vectors	in	cancer	virotherapy	
Non-replicating SFV vectors have been widely used in cancer virotherapy as these 
vectors can induce antitumoural activities through apoptosis or induction of immune 
responses against tumour cells. SFV vectors have been engineered to express various 
cytokines for the enhancement of antitumour immune responses (Quetglas, Ruiz-
Guillen et al. 2010). Various oncolytic SFVs have also been tested in preclinical models 
of cancer virotherapy. One of the most studied oncolytic SFV is the VA7-EGFP vector, a 
derivative of the naturally attenuated A7(74) strain (Vaha-Koskela, Tuittila et al. 2003). 
Preclinical studies using this virus have shown promising efficacy against various 
human tumours in xenograft mice models (Vaha-Koskela, Kallio et al. 2006; Ketola, 
Hinkkanen et al. 2008; Maatta, Makinen et al. 2008; Heikkila, Vaha-Koskela et al. 2010). 
However, recently it has been shown that the potent antitumour efficacy obtained in 
immunocompromised mice models do not translate into efficacy in immunocompetent 
mice models harbouring syngeneic tumours (Ruotsalainen, Martikainen et al. 2012; 
Vaha-Koskela, Le Boeuf et al. 2013). Unexpectedly, in both of these studies it was also 
reported that the attenuated SFV strains used to treat syngeneic experimental glioma, 
the viruses were shown to infect normal brain tissue as opposed to tumour tissue, 
necessitating further increase of the safety of these vectors via e.g. miRNA-mediated 
neuronal attenuation. 
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2 AIMS	OF	THE	STUDY	
The aim of this doctoral thesis was to investigate whether tissue-specific miRNA 
expression patterns could be exploited to modify the tissue tropism of oncolytic viruses 
for increased safety. The specific aims were: 
1. To study whether liver-specific miR122 expression could be exploited to de-
target adenovirus replication from the liver 
2. To study whether neuron-specific miR124 expression could be exploited to de-
target Semliki Forest virus replication from neurons 
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3 MATERIALS	AND	METHODS	
3.1 Cell	lines	and	human	liver	and	tumour	tissues	
All cell lines used in this study were cultured in the recommended growth media and 
maintained in a humidified atmosphere in the presence of 5% CO2 at  37  ºC.  Table  3  
summarizes the cell lines used. 
Table 3. Cell lines used in this doctoral thesis. 
Cell line Description Source Study 
Huh7 Human hepatocellular carcinoma Mark Harris I-III 
HeLa Human cervical cancer  ATCC I,III 
PC3 Human prostate cancer ATCC I 
A549 Human lung cancer ATCC I,II 
293 Human embryonic kidney  Microbix II 
293FT Human embryonic kidney  Life technologies I 
Tera-2 Human embryonal carcinoma ATCC III 
U87 Human primary glioblastoma ATCC III 
BHK-21 Syrian hamster kidney fibroblast ATCC III 
Vero African green monkey fibroblast University of Turku III 
HCT116 Human colorectal cancer ATCC II 
HEp-2 HeLa derivative cell line ATCC II 
 
Healthy human liver and colorectal carcinoma samples (II) were received from patients 
undergoing a surgical removal of liver metastasised colorectal carcinoma. Healthy liver 
was obtained from the resection marginal of the removed tumours. The tissue samples 
were sliced at 300-500 μm with a Krumdieck precision-cut tissue slicer (Alabama 
Research and Development Corporation) and cultured on a plate rocker in a humidified 
atmosphere  in  the  presence  of  5%  CO2 at 37 ºC. Culture media used was William’s 
medium E (Life Technologies) supplemented with 10% foetal calf serum and 1% 
Glutamax-I (Life Technologies) and 1% penicillin/streptomycin. 
3.2 Construction	of	miRNA-targeted	viruses	(I-III)	
A  shuttle  vector  pSEMII  was  created  from  pSE1  (Bauerschmitz,  Guse  et  al.  2006)  by  
engineering a wild-type E1A promoter/enhancer region to drive wild-type E1A 
expression  and  a  novel  MluI  site  into  the  3’UTR  of  the  E1A  transcript.  A  miRNA-
targeted shuttle vector pShuttle122 was derived from pSEMII by inserting three target 
elements for miR122 into the novel MluI site. The target elements were cloned using 
annealed oligonucleotides (5’- CGCGTGGAGTGTGACAATGGTGTTTGTACCGGT -3’ and 5’- 
CGCGACCGGTACAAACACCATTGTCACACTCCA -3’) including the miR122 target element. 
pShuttleK and pShuttleK-122 was derived from pSEMII and pShuttle122, respectively, 
by inserting annealed oligonucleotides (5’-CGCGCACCATGGTGTCGACG-3’ and 5’-
CGCGCGTCGACACCATGGTG-3’) into the 5’UTR of the endogenous starts codon (ATG) to 
create an additional out-of-frame start codon. To create Ad5/3-122 (I), a homologous 
recombination between pShuttle122 and Ad5/3-∆24 (Kanerva, Mikheeva et al. 2002) 
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was carried out. To create Ad5/3K (I) and Ad5/3K-122 (I), a homologous recombination 
between pShuttleK or pShuttleK-122 and Ad5/3-∆ was carried out respectively. 
pShuttle 6x122 (II) was made similarly to pShuttle122 except instead of three miR122 
target elements, six target elements were inserted into the MluI site in the 3’UTR of 
the E1A transcript. To create Ad5T122 (II), a homologous recombination between 
pShuttle 6x122 and Ad5-∆24 (Fueyo, Gomez-Manzano et al. 2000) was carried out. The 
amplification of infectious adenoviral particles were carried out using A549 cells and 
purified by ultracentrifugation using double cesium chloride gradient or by column 
filtration (Takara Bio Incorporation). Titres of the purified virus stocks were determined 
by a 50% tissue culture infectious dose (TCID50) method using 293 cells.  
To create SFV4-miRT122 and SFV4-miRT124 viruses (III),  a  plasmid  containing  the  
genomic sequence of SFV4 (Liljestrom, Lusa et al. 1991) was modified by engineering a 
novel NdeI site upstream of the sequence coding for protease cleavage site locating 
between nsp3 and nsp4 coding regions. A synthetic DNA sequence including duplicated 
sequence coding for protease cleavage site and sequences for six target elements for 
miR122 or miR124 was inserted between upstream naturally existing XhoI site and the 
novel NdeI site resulting in a plasmid carrying six miRNA-target elements flanked by 
sequences coding for the protease cleavage sites. All SFV4 viruses were produced from 
in vitro transcribed RNA by transfection into BHK-21 cells and subsequently titrated by 
plaque titration method using Vero cells. The correct sequences of miRNA target 
elements of all viruses created were confirmed by sequencing. All viruses used in this 
doctoral thesis are summarized in table 4. 
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Table 4. Viruses used in this doctoral thesis. 
Virus Description   Source Study 
Ad5/3-122 
Ad5 virus with 3xmiR122 target elements in the 3'UTR of 
E1A + chimeric receptor-binding knob domain of Ad3 
 
This study I 
Ad5/3-∆24 Ad5 virus with 24-bp deletion in CR2 of E1A + chimeric 
receptor-binding knob domain of Ad3 
 
(Kanerva, Zinn 
et al. 2003) 
I 
Ad5/3K Ad5 virus with low E1A expression phenotype + chimeric 
receptor-binding knob domain of Ad3 
 
This study I 
Ad5/3K122 
Ad5 virus with 3xmiR122 target elements in the 3'UTR of 
E1A + low E1A expression phenotype + chimeric 
receptor-binding knob domain of Ad3 
 
This study I 
Ad5T122 
Ad5 virus with 6xmiR122 target elements in the 3'UTR of 
E1A 
 
This study II 
Ad5Luc1 Non-replicating Ad5 virus with luciferase gene under 
CMV promoter replacing E1 region 
 
(Krasnykh, 
Belousova et 
al. 2001) 
II 
Ad5 wild type Adenovirus 5 
 
II 
SFV4-miRT122 SFV4 virus with 6xmiR122 target elements between nsp3 and nsp4 
 
This study III 
SFV4-miRT124 
SFV4 virus with 6xmiR124 target elements between nsp3 
and nsp4 
 
This study III 
SFV4 wild type SFV4 virus 
  
(Liljestrom, 
Lusa et al. 
1991) 
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3.3 Reporter	plasmids	(I)	
Variable copy number of miR122 target elements were introduced by annealing and 
ligating oligonucleotides 5’- CGCGTGGAGTGTGACAATGGTGTTTGTACCGGT -3’ and 5’- 
CGCGACCGGTACAAACACCATTGTCACACTCCA -3’ into the 5’UTR or 3’UTR of firefly 
luciferase cDNA in the pcDNA3-derived plasmid pSIRNALUC.  
3.4 Animals	(II,	III)	
Animal experiments were approved by the Finnish Committee for Care and Use of 
Animals in Experiments (III) and the experimental animal committee of the University 
of Helsinki and the provincial government of Southern Finland (II). 3-5 week-old BALB/c 
mice  were  purchased  from  Taconic.  3-5  week-old  NMRI  nude  mice  were  purchased  
from Harlan laboratories. 3-5 week-old C57bl/6 mice were purchased from the 
Laboratory Animal Center of the University of Helsinki. All animals were quarantined 
for two weeks preceding the experiments. 
3.5 In	vitro	experiments	
3.5.1 Dual-luciferase	assays	(I,	II)	
Empty or miR122 target elements containing reporter plasmids were transfected 
together with pCDNA-Renilla and 24 to 48 h posttransfection luciferase activities where 
measured using a dual-luciferase assay system (Promega). Reporter plasmid 
transfections were also done in the presence of miRIDIAN miR122 inhibitor 
(Dharmacon) at final concentration of 100 nM (I). 
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3.5.2 Cell	viability	assays	(I-III)	
Huh7, HeLa, PC3 and A549 cell lines (I) or Huh7, HTC116, Hep-2 and A549 cell lines (II) 
were infected with different adenoviruses at MOI of 0.05 or Huh7, BHK-21, HeLa, Tera-
2  and  U87  cell  lines  (III)  were  infected  with  different  SFVs  at  MOI  of  0.1  and  cell  
viability  was  measured  24  h  to  9  days  postinfection  using  CellTiter  96  AQueous One 
solution cell proliferation assay (Promega). A multiwell plate reader (Multiscan EX, 
Thermo Fisher Scientific) was used to determine the optical density of the reactions at 
492 nm. 
3.5.3 Quantification	of	viral	replication	(I-III)	
Infected A549 and Huh7 cells (I) were harvested at three (A549) and five (Huh7) days 
postinfection and the amount of cell-associated infectious virus was quantified.  
Supernatant of the infected cultured human liver and liver metastatic colorectal cancer 
tissue slices (II) were harvested at 1h, 1d, 3d and 5d and the amount of infectious virus 
was quantified. All adenovirus titres were determined by TCID50. Briefly, 293 or 293FT 
cells were seeded in 96-well plates (104 cells/well) and the next day eight serial 10-fold 
dilutions of viral samples were added to the 96-well plates.  After 10 days of incubation 
the wells with CPE were counted and viral titres were calculated by the Spearman-
Kärber  method.  For  Semliki  Forest  virus  titrations  of  mouse  tissues  (III), snap-frozen 
brain and liver samples were homogenised in 1% bovine serum albumin (BSA)-
phosphate buffered saline (PBS) and centrifuged at 4500 g for 5 minutes. The collected 
supernatant was used for virus titration. All Semliki Forest virus titres were determined 
by plaque titration.  
3.5.4 Western	blot	analysis	(I,	III)	
Infected cells were lysed with 1% NP-40 lysis buffer (150 mM NaCl; 50 mM Tris-HCl, pH 
7.9; 1% Nonidet P-40) in the presence of protease inhibitors. Protein concentrations 
were determined by the Bio-Rad Protein Assay (Bio-Rad), and 50 μg (I) or 10 μg (II) of 
each sample was separated by SDS-PAGE and then blotted onto a nitrocellulose 
membrane  (Bio-Rad).  After  blocking  overnight  at  4  ºC  with  PBS  +  0.05%  Tween  20  
containing 5% non-fat dry milk, the membranes were treated with mouse monoclonal 
antibody specific to adenoviral E1A proteins (Santa Cruz Biotechnology) or adenovirus 
infected patient serum (a kind gift from Jukka Suni, HUSLAB, Helsinki) as primary 
antibodies (I) or treated with rabbit polyclonal antibodies against nsp3 and nsp4 (kindly 
donated by Dr. Tero Ahola, University of Helsinki) or rabbit anti-SFV against envelope 
and capsid proteins as primary antibodies (III) and then with horseradish peroxidase-
conjugated secondary antibodies against mouse or human immunoglobulins 
(DakoCytomation) (I) or with IRdye 800 secondary antibody against rabbit 
immunoglobulins (LI-COR) (III). Enhanced chemiluminence detection system (ECL; 
Millipore) (I)  or  Odyssey infrared imaging system (LI-COR) (III) was used for detection 
and quantification of viral proteins. 
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3.5.5 Quantitative	RT-PCR	(I,	III)	
Total RNA was extracted from infected cells using GenElute Mammalian Total RNA 
Miniprep Kit (Sigma-Aldrich). A RevertAid M-MuLV reverse transcriptase (Thermo 
Fisher Scientific)  was used for  cDNA synthesis  (I, III).  In  the study (I): Oligonucleotide 
sequences for amplification of E1A S13 gene were: forward primer 5’-
TCCGGAGCCGCCTCACCTTTC-3’ and reverse primer 5’-
GGCTCAGGTTCAGACACAGGACTGTAG-3’. Oligonucleotide sequences for amplification 
of the human house-keeping gene GAPDH were: forward 5’-
GAGTCAACGGATTTGGTCGT-3’ and reverse 5’-TTGATTTTGGAGGGATCTCG-3’. PCR was 
run using a LightCycler Instrument (Roche) with DyNAmo™ Capillary SYBR® Green qPCR 
Kit (Finnzymes). After an initial incubation at 95°C for 10 min, 35 amplification cycles 
were conducted as follows:  denaturation at  95°C for  10 s,  annealing at  55°C for  10 s,  
and extension at 72°C for 12 s. To quantify the differences of E1A mRNA levels in Huh7 
cells the LightCycler data point curves were compared to similar analyses obtained 
using a dilution standard, and graphed as percentage relative to the specimen with 
highest expression. In the study (III): Oligonucleotide sequences for amplification of 
SFV positive strand genome were: forward primer 5’-TGGAGCTGACCACAGACTTG-3’ 
and reverse primer 5’-  GGCCACAACGTCAGTATCTC-3’.  PCR was run using an Mx3005p 
QPCR System (Stratagene) with Power SYBR green PCR master mix (Applied 
Biosystems). After an initial incubation at 95°C for 10 min, 40 amplification cycles were 
conducted as follows: denaturation at 95°C for 15 s, annealing and extension at 60°C 
for 1min. 
3.5.6 Immunohistochemistry	(II,	III)	
Brain tissue samples from mice displaying neurological symptoms (III) or human liver 
and liver metastatic colorectal cancer tissue slices (II) were fixed and embedded into 
paraffin blocks. The samples were cut into 7-μm sections using microtome and IHC 
analyses were performed using a Vectastain ABC kit (Vector laboratories) with a 
polyclonal anti-SFV antibody (II) or using Dako envision system (Dako) with an antibody 
against adenovirus 5 E1A protein (Thermo Fisher Scientific). Detailed descriptions of 
sample preparations can be found in the original publications.  
3.6 In	vivo	experiments	
3.6.1 Animal	experiments	in	study	II	
For the experiments assessing liver toxicity, adult 5-7 week old female C57bl/6 mice 
were systemically infected with 1x109 PFU  of  Ad5  or  Ad5T122  by  tail  vein  injection.  
After 72h post-infection blood was taken from mice by cardiac puncture and serum 
samples were added to ALAT reagent (Thermo Fisher Scientific) and the change in 
absorbance (340nm) per minute was monitored. Units of ALAT activity were calculated 
according to manufacturer’s instructions. For the experiments assessing oncolytic 
potency  of  the  viruses,  adult  5-7  week  old  female  NMRI  nude  mice  were  
subcutaneously injected with 3x106 A549 cells into both flanks and animals were 
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monitored for tumour appearance. Mice were treated on days 0, 2 and 4 by 
intratumoural injection at 107 PFU/tumour with either Ad5 or Ad5T122. Tumour 
volumes were measured using hand-held calliper and MedCalc software was used to 
calculate serial measurements for statistical analysis. More detailed description of the 
experiments can be found in the original publication (II). 
3.6.2 Animal	experiments	in	study	III	
Adult  5-7  week  old  female  Balb/c-mice  (Taconic)  were  infected  with  SFV4,  SFV4-
miRT122 or SFV4-miRT124 by injecting 1x106 PFU intraperitoneally or 100-1x105 PFU 
intracranially. For intracranial injections mice were sedated and kept under isoflurane 
gas anesthesia. Viruses were injected into the caudate putamen of mice. After virus 
injection mice were monitored for neurological symptoms and distress. Symptoms 
were graded as follows: 0: no symptoms; 1: mild symptoms (ruffled fur, hunched back, 
weakness of limbs, optic neuritis); 2: partial paralysis of hind limbs; 3: paralysis of hind 
or front limbs, 4: severe paralysis, tetraplegia, 5: moribund/dead. In the case of severe 
neurological symptoms, paralysis (grade 3 or higher) or distress mice were sacrificed 
and tissue samples (brain, liver and blood) were collected. More detailed description of 
the experiments can be found in the original publication (III). 
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4 RESULTS		
4.1 Development	of	liver	de-targeted	adenoviruses	(I,	II)	
4.1.1 Targeted	destruction	of	adenovirus	E1A	mRNA	by	liver-specific	miR122	(I)	
To test the potential of miR122 to suppress foreign genes containing miR122 target 
elements perfectly complementary to miR122 sequence, we constructed reporter 
plasmids that contained variable copy number of miR122 target elements in the 5’ or 
3’UTR  of  a  firefly  luciferase  (FFluc)  gene  (see  fig.  1A  in  I). Dual-luciferase assays with 
plasmids containing miR122 target elements showed that increasing copy number of 
target elements had cumulative effect on the suppression of the FFluc expression in 
liver-derived Huh7 cells expressing high amounts of miR122 but not in non-hepatic cells 
devoid of miR122 expression. Co-transfection with synthetic miR122 inhibitor 
(antagomiR-122) released the suppression of FFluc expression in Huh7 cells confirming 
that the inhibitory effect of miR122 target elements was specifically mediated by 
miR122 (see figs. 1B and C in I). 
To test whether miR122 target elements could suppress the expression of E1A of a 
replication-competent adenovirus 5, we constructed an adenovirus containing three 
target elements for miR122 in the 3’ UTR of E1A gene (Ad5/3-122). E1A protein levels 
in Ad5/3-122-infected Huh7 cells where drastically lower than in Ad5/3-∆24-infected 
Huh7 cells whereas in A549 cells the E1A levels were similar with both viruses 
indicating that miRNA-mediated suppression of E1A in the context of a replication-
competent adenovirus can occur (see fig. 2A in I).  To  further  test  if  the  miRNA-
mediated suppression of E1A was due to reduced levels of E1A mRNA rather than 
reduced E1A translation, RNA was extracted from Huh7 and A549 cell cultures infected 
for  1-3  days  with  Ad5/3-∆24  or  Ad5/3-122  viruses  and  E1A  mRNA  levels  were  
measured by quantitative RT-PCR. The levels of E1A mRNA produced in A549 cells were 
similar for both viruses whereas E1A mRNA levels of Ad5/3-122 produced in Huh7 cells 
were significantly reduced compared to that of Ad5/3-∆24 (see fig. 2B in I), indicating 
that the miRNA-mediated suppression occurs via mRNA destruction (endonucleolytic 
cleavage-pathway) rather than via translational repression.  
Despite the very potent and miR122-specific suppression of E1A mRNA levels, the viral 
replication of Ad5/3-122 was only moderately attenuated as compared to Ad5/3-∆24 in 
Huh7 cells based on cell viability assays and the notion that the levels and expression of 
total adenoviral proteins revealed similar patterns for both viruses (see fig. 2A in I). 
Thus, although E1A levels could be drastically reduced by miRNA-mediated suppression 
in Huh7 cells, the level of reduction was not sufficient to have a significant impact on 
viral replication. In order to overcome this problem, we generated an adenovirus that 
has a uniformly reduced E1A expression in all cell types by inserting an ectopic 
translation initiation site into the 5’UTR of E1A mRNA in the wrong reading frame 
relative to E1A reading frame. This adenovirus, named Ad5/3K, replicated similarly to 
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Ad5/3-∆24 in both Huh7 and A549 cells despite the reduced E1A expression (see fig. 3A 
in I).  Based  on  this  finding,  we  generated  a  miRNA-targeted  derivative  of  Ad5/3K  
containing three target elements for miR122 in the 3’ UTR of E1A gene (Ad5/3K-122). 
The infection of Huh7 cells with Ad5/3K or Ad5/3K-122 displayed dramatic differences 
in the E1A protein levels. The E1A levels in the Ad5/3K-infected Huh7 cells increased 
gradually over the 5-day incubation period, whereas the E1A levels in the Ad5/3K-122-
infected Huh7 cells remained undetectable in all time points examined (see fig. 3B in I). 
Also, in contrast to the increasing levels of total adenoviral proteins in Ad5/3K-infected 
Huh7 cells, the levels of total adenoviral proteins in Ad5/3K-122-infected Huh7 cells 
remained undetectable in all time points examined (see fig. 3B in I). Importantly, no 
difference in viral protein levels between Ad5/3K-infected A549 cells and Ad5/3K-122-
infected A549 cells was observed (see fig. 3B in I). In agreement with the undetectable 
levels of adenoviral proteins in Ad5/3K-122-infected Huh7 cells, infection with Ad5/3K-
122 did not induce detectable cytopathic effect (CPE) in Huh7 cells even upon 2-week 
observation period. In other cell lines tested the CPE induced with Ad5/3K-122 
infection was similar to CPE induced with Ad5/3K infection (see fig.4A in I). 
To quantify the suppression of replication by miR122, we measured the cell-associated 
infectious virus produced by Huh7 and A549 cells infected with Ad5/3K-122 or Ad5/3K. 
Five days postinfection with the viruses at  a  MOI of  0.05,  only  79 PFU/ml of  Ad5/3K-
122 compared to 1.0x106 PFU/ml  of  Ad5/3K  could  be  recovered  from  Huh7  cells.  In  
A549 cells, both viruses had similar rate of replication confirming miR122-specific 
suppression of Ad5/3K-122 replication (see fig. 5 in I).  
4.1.2 Construction	and	in	vitro	characterization	of	miR122-targeted	adenovirus	
based	on	serotype	5	(II)	
To  generate  a  miRNA-targeted  derivative  of  wild-type  adenovirus  5  (Ad5T122),  we  
inserted six target elements for miR122 in the 3’ UTR of E1A gene (see fig. 1 in II). To 
compare the oncolytic potency of Ad5T122 and wild-type adenovirus 5 (Ad5) in vitro, a 
panel of cancer cell lines where infected with these viruses and a non-replicating 
control virus (Ad5Luc1) and the amount of lytic cell killing was measured using a cell 
viability assay. As expected, the non-replicating A5Luc1 did not have a significant effect 
on the cell  viability  of  any of  the cell  types tested.  Infection with Ad5 lead to potent 
lysis in all the cell lines tested. Infection of the non-hepatic cell lines with Ad5T122 lead 
to  lysis  similar  to  that  of  Ad5.  In  contrast,  lysis  caused  by  Ad5T122  was  strongly  
suppressed in the liver-derived cell line Huh7, indicating a miR122-specific attenuation 
of  Ad5T122  (see  fig.  2  in  II). To further confirm that the attenuation of Ad5T122 in 
Huh7 cells was due to silencing by miR122, we generated stable cell lines in which the 
key  component  of  the  miRNA  machinery,  Argonaute  2  (Ago2)  had  been  targeted  for  
silencing with anti-Ago2 short hairpin RNAs (shRNAs). Infection of those cell lines with 
Ad5 or Ad5T122 resulted in very similar production of CPE. The effect of miR122 
inhibition on virus replication was also examined by transfecting Huh7 cells with 
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MIRIDIAN miR122 inhibitor prior to infection with Ad5 or Ad5T122. Also in this case, 
the  suppressive  effect  of  miR122  target  elements  on  Ad5T122  replication  was  
abolished (see supplementary fig. S2 in II) 
4.1.3 Characterization	of	Ad5T122	replication	in	human	liver	and	in	colorectal	
carcinoma	(II)	
To further examine the miR122-specific suppression of Ad5T12, we used an 
experimental system based on ex vivo culturing of precision-cut human liver tissue 
slices. This ex vivo human liver infection model is one of the best models for preclinical 
evaluation of adenoviral induced liver toxicity, and allows the examination of 
productive adenoviral infection in the presence of all the cell types within the context 
of the normal three-dimensional architecture of the human liver. This same 
experimental system was also used to examine the replication of Ad5 and Ad5T122 in 
human tumour tissue, more precisely, in human colorectal carcinoma liver metastases. 
To examine the suppression of Ad5T122 replication in human liver, we infected liver 
tissue slices with Ad5 or Ad5T122 and followed the infections for up to 5 days. Similarly, 
human tumour tissue slices were also infected with these viruses and were followed 
for up to 5 days. The immunohistochemical examination of the Ad5-infected tissue 
slices with an antibody against E1A protein showed considerable increase in signal 
intensity in liver as well as in tumour as the infection proceeded indicating productive 
replication in both tissues. The immunohistochemical examination of the Ad5T122-
infected tumour tissue slices showed similar increase in signal intensity as observed 
with Ad5. In contrast, the immunohistochemical examination of the Ad5T122-infected 
liver tissue slices did not show any specific signal and appeared identical to the 
uninfected liver tissue controls (see fig. 3 in II).  
To directly examine the rate of productive replication of Ad5 and Ad5T122 in the 
human liver and tumour tissues, the amount of infectious virus was quantitated at 
different time points after initial infection of liver and tumour tissues with Ad5 or 
Ad5T122. The infectious titre of Ad5 in the liver tissue supernatant increased gradually 
during the five-day follow up period, exceeding the input dose by 68-fold for liver #1 
and by 27-fold for liver #2 at 5d postinfection (p.i). By contrast, very little Ad5T122 was 
found in the liver tissue supernatant, and even at 5d p.i. the titre for liver #1 only 
slightly (1.3-fold) exceeded the input level (1h p.i.) and for the liver #2 the titre 
decreased to less than half (0.47-fold) of the input level (see fig. 4A in II). In the tumour 
tissue samples, both viruses replicated to the same extent (see fig. 4B in II). 
4.1.4 Evaluation	of	liver	toxicity	of	systemically	administered	Ad5T122	(II)	
Although human adenovirus 5 does not productively replicate in mouse tissues, 
systemic viral injection is associated with hepatotoxicity manifesting in elevated serum 
levels of liver enzyme alanine aminotransferase (ALAT). To investigate the toxicity of 
systemically administered Ad5T122, we infected 1x109 PFU  of  Ad5,  Ad5T122  or  PBS  
into the tail vein of C57bl/6 mice. 72h post-injection the animals were sacrificed and 
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serum ALAT levels were measured. Mice injected with Ad5 showed markedly increased 
ALAT levels compared to PBS injected mice, indicating hepatotoxicity of Ad5 following 
systemic administration. By contrast, mice injected with Ad5T122 showed ALAT levels 
indistinguishable from those of PBS injected mice (see fig. 5 in II). 
4.1.5 Oncolytic	potency	of	Ad5T122	in	a	lung	cancer	xenograft	model	(II)	
To confirm that the severe attenuation of Ad5T122 replication in liver was not 
associated with reduced replication in tumour tissue in vivo, we compared the 
oncolytic potency of Ad5T122 and Ad5 in a mouse lung cancer xenograft model. Nude 
mice bearing an established subcutaneous A549 lung cancer xenografts were treated 
intratumourally on days 0, 2, and 4 with 1x107 PFU of Ad5, Ad5T122 or a corresponding 
volume of  PBS,  and tumour growth was monitored for  12 days following the start  of  
the treatment. Tumours in the PBS treated group of mice showed rapidly increasing 
growth and by the end of the 12-day follow up, tumours had reached more than 5x the 
initial volume. Tumours in the Ad5 and Ad5T122 treated groups of mice showed 
similarly reduced growth and starting from the day 8, a statistically significant 
reduction in tumour growth was observed with both viruses compared to the PBS 
treated group (see fig 6 in III).  
 
4.2 Development	of	miRNA-targeted	Semliki	forest	viruses	for	the	
attenuation	of	lethal	neurovirulence	(III)	
4.2.1 Construction	and	in	vitro	characterization	of	miRNA-targeted	Semliki	forest	
viruses	(III)	
For the development of neuronally attenuated Semliki Forest virus (SFV), we inserted 
six target elements for a neuron-specifc miRNA miR124 into the genome of SFV4 (SFV4-
miRT124).  As  a  control  virus  for  efficient  evaluation  of  the  miRNA-targeting  in  the  
context of replication competent SFVs in vitro, we inserted six target elements for liver-
specific miR122 into the genome of SFV4 (SFV4-miRT122). Initially, three different 
strategies to generate miRNA-regulated SFV4 were tested. Target elements for miR122 
were inserted in 5’UTR, 3’UTR or in the middle of the genome between nsp3 and nsp4. 
When inserted in the middle of the genome, an additional protease cleavage site was 
introduced between nsp3 and nsp4 and the target elements were inserted between 
the additional and original protease cleavage sites. Characterization of these modified 
viruses revealed that the most effective place for the target insertion was between 
nsp3 and nsp4, and this strategy was then chosen for all subsequent experiments (see 
fig 1 in III for schematic presentation of the miRNA-targeted SFV4 viruses).  
To see whether the insertion of additional protease cleavage site and miRNA-target 
elements between nsp3 and nsp4 affected the correct proteolytic processing of nsp3 
and nsp4, BHK-21 cells were infected with SFV4-miRT122, SFV4-miRT124 or wild-type 
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SFV4 at MOI of 1. Twelve hours p.i. cells were collected and the proteolytic processing 
of nsp3 and nsp4 was analysed by Western blotting. All viruses showed bands of similar 
size for both nsp3 and nsp4 indicating correct processing of these proteins from the 
polypeptide (see fig. 2A in III). 
To evaluate the potency of miRNA-targeting to restrict SFV4 replication, we infected 
miR122-expressing Huh7 cells and miR122-negative A549 cells with SFV4-miRT122, 
SFV4-miRT124 or wild-type SFV4. Six hours, 12h or 24h postinfection of Huh7 cells and 
24h postinfection of A549 cells, the capsid and envelope protein production was 
monitored by Western blotting. In BHK-21 cells, SFV4-miRT122 and SFV4-miRT124 
produced  similar  amounts  of  capsid  and  envelope  proteins  as  compared  to  SFV4.  In  
Huh7 cells, SFV4-miRT124 and SFV4 produced similar amounts of capsid and envelope 
proteins at all time points analysed whereas viral protein production of SFV4-miRT122 
was strongly reduced,  most  strikingly  at  the early  time points  see figure 2B in III). To 
test if the miRNA-mediated suppression of viral proteins in SFV4-miRT122-infected 
Huh7  cells  was  due  to  endonucleolytic  cleavage  of  viral  genomic  RNA  rather  than  
translational suppression, we infected Huh7 and A549 cells with SFV4-miRT122, SFV4-
miRT124 or wild-type SFV4 at an MOI of 0.1 and measured the levels of genomic RNA 
by quantitative RT-PCR at 24h p.i. (see fig. 2C in III). In BHK-21 cells, no differences in 
the levels of viral genomic RNA were seen between the viruses. In Huh7 cells infected 
with SFV4-miRT122, the levels of viral genomic RNA were strongly (over 83%) reduced 
as compared to the cells infected with SFV4 or SFV4-miRT124. These results confirmed 
that the miRNA-specific suppression occurred via endonucleolytic cleavage of the viral 
genomic RNA. 
For the in vitro evaluation of the oncolytic potency of miRNA-targeted SFV4 viruses, we 
infected a panel of cell lines with SFV4-miRT122, SFV4-miRT124 or wild-type SFV4 at an 
MOI of 0.1 and the amount of cell destruction was measured using a cell viability assay. 
Infection with SFV4 or SFV4-miRT124 lead to a potent destruction of all cell lines tested. 
By contrast, infection with SFV4-miRT122 lead to a potent destruction of all cell lines 
except miR122-expressing Huh7 cell line, thus indicating that the replication of SFV4-
miRT122 was specifically suppressed by miR122. Also, the insertion of miRNA target 
elements into the SFV4 genome did not affect the oncolytic potency of these viruses in 
vitro. 
4.2.2 In	vivo	characterization	of	SFV4-miRT124	(III)	
To evaluate the replication and viral spread of the miRNA-targeted SFV4s in vivo, adult 
5-7-week old BALB/c mice were infected intraperitoneally with 1x106 PFU of SFV4-
miRT122, SFV4-miRT124 or wild-type SFV4. Since miR122 is not expressed in the CNS, 
we used SFV4-miRT122 as a control virus to rule out any nonspecific effects on viral 
replication  due  to  the  insertion  of  the  target  elements  into  the  viral  genome.  Mice  
infected  with  SFV4  started  to  display  neurological  symptoms  at  day  4  p.i.  leading  to  
severe symptoms or death in 4 out of 8 mice within the 14 day follow-up period. Mice 
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infected with SFV4-miRT122 also started to display neurological symptoms at day 4 p.i. 
eventually  leading  to  severe  symptoms  or  death  in  6  out  of  8  mice.  No  statistical  
difference in survival between SFV4- and SFV4-miRT122-infected groups of mice could 
be observed. By contrast, in the group of SFV4-miRT124-infected mice, only 1 mouse 
out of 8 mice developed severe neurological symptoms and had to be sacrificed within 
the 14 day follow-up period. Importantly, a significantly increased survival benefit was 
obtained over the control SFV4-miRT122 group (P=0.0106, log-rank test), indicating an 
attenuated replication of SFV4-miRT124 in the CNS.  
To examine whether the severe neurological outcome of the single mouse from the 
group  of  SFV4-miRT124  infected  mice  was  due  to  mutational  loss  of  the  target  
elements, we isolated RNA from the brain of this animal. The region containing the 
target elements was amplified by RT-PCR and 18 individual clones containing the 
amplified PCR fragments were sequenced. 16 out of 18 clones showed no mutations in 
the target element region and 1 clone had lost 2 target elements but the remaining 4 
were intact. Only 1 clone out of 18 had lost all the target elements and had reverted to 
wild-type like virus. Although these result showed that mutations in the target region 
can occur, the late emergence and low frequency of the escape mutants indicates that 
this might be relatively rare event and unlikely to explain the severe outcome of 
infection in this animal. 
Viral replication in the periphery was analysed by titration of the sera of the infected 
mice  at  days  1,  2  and  3  p.i.  High  level  of  viremia  was  seen  with  all  viruses  at  1d  p.i.  
rapidly dropping to near undetectable levels at the following days. All viruses showed 
comparable serum titres indicating a wild-type-like replication of SFV4-miRT124 and 
SFV4-miRT122 in the periphery (see fig. 4B in III). Viral load from the brains of the 
infected mice was also analysed. Titres of the SFV4- and SFV4-miRT122 infected mice 
brain homogenates showed comparable, continuously increasing amount of virus 
between days 2 and 4 p.i. Titres of the SFV4-miRT124-infected mice brain 
homogenates showed an increase in viral load until day 3 p.i., and remained at the 
same level at day 4 p.i. However, the average brain titre for SFV4-miRT124 remained at 
103 PFU/g while the average titres for SFV4 and SFV4-miRT122 increased to 105 to 106 
PFU/g  (see  fig.  4C  in  III). To further study the attenuation of SFV4-miRT124 in the 
infected mice brain, we evaluated the antiviral interferon responses elicited by the 
viruses by measuring the levels of interferon-β (IFN-β) from the brain homogenates of 
infected animals. High levels of IFN-β could be measured from the brains of SFV4-
miRT122- and SFV4-infected animals, indicating a clear host response against these 
viruses.  By  contrast,  no  IFN-β could  be  measured  from  the  brains  of  SFV4-miRT124-
infected animals correlating well with the attenuated replication of SFV4-miRT124 in 
the CNS (see fig. 5 in III). 
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To study the distribution and amount of viruses in brain, immunohistochemical analysis 
of brain samples collected from the infected mice was carried out. Analysis of a brain 
sample from the SFV4-miRT124-infected mouse suffering from severe neurological 
symptoms revealed only a limited focal infection of the brain whereas the brains of 
SFV4- and SFV4-miRT122-infected mice suffering from neurological symptoms showed 
a wide-spread neuronal infection of the midbrain, thalamus and cerebellum (see fig. 6 
in III).  
4.2.3 Pre-infection	with	SFV4-miRT124	induces	protective	immunity	against	lethal	
SFV	challenge	(III)	
To test whether the SFV4-miRT124-infected mice that survived the intraperitoneal 
virus administration had develop immunity against SFV, an indicator of robust 
peripheral replication, 5 surviving mice were intraperitoneally injected with 1x106 PFU 
of the lethal L10 strain (see fig.7 in III). All mice previously infected with SFV4-miRT124 
survived the lethal L10 challenge and remained asymptomatic for the 20-day follow-up 
period. By contrast, all mice without preceding SFV4-miRT124 infection died within 4 
days.  
4.2.4 Intracranially	administered	SFV4-miRT124	leads	to	restricted	infection	of	
the	corpus	callosum	(III)	
To examine the neuronal attenuation of SFV4-miRT124 when administered directly into 
the brains of mice, 100, 10 000 and 100 000 PFU of SFV4-miRT122, SFV4-miRT124 or 
SFV4 was intracranially injected into groups of BALB/c mice. While a significantly 
increased survival benefit (P ≤ 0.0009, log-rank test) of the SFV4-miRT124-infected 
mice was obtained over the SFV4-miRT122 and SFV4-infected groups of mice, all mice 
eventually developed lethal neurological symptoms (see fig. 8 in III). 
Immunohistochemical analysis of the brains of these mice revealed that while SFV4-
miRT122 caused a widespread infection of the brain involving also the Purkinje neurons 
of the cerebellar cortex, infection with SFV4-miRT124 was dramatically restricted in the 
neurons. Only a few infected neurons were seen, and the virus was predominantly 
infecting the oligodendrocytes of the corpus callosum (see fig. 9 in III). 
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5 DISCUSSION	
5.1 Developing	liver-detargeted	adenoviruses	for	increased	safety	(I,II)	
Oncolytic adenoviruses are considered to be a promising tool for the treatment of 
cancer. However, liver tropism restricts their systemic use and adenoviruses can cause 
liver toxicity.  Various approaches have been developed to circumvent the liver toxicity 
and to increase tumour selectivity, including the use of tumour specific promoters to 
drive the expression of E1A, deletion of CR2 in the E1A, deletion of E1B55k reading 
frame, chemical or genetic modifications of capsid proteins (Kanerva and Hemminki 
2004). We wanted to test whether miRNAs can be exploited to de-target adenovirus 
replication from the liver. 
In the study I, we showed that the expression of a liver-specific microRNA miR122 can 
be exploited to create an adenovirus that fails to replicate in the liver-derived cells. We 
first tested the potency of miR122 to regulate foreign genes when artificial target 
elements for miR122 were introduced into the 5’UTR or 3’UTR or into both the 5' and 
3'UTR of the firefly luciferase (FFluc) mRNA. Dual-luciferase assays showed profound 
and miR122-specific suppression of FFluc activities when tested with various different 
cell  lines.  These  results  encouraged  us  to  test  the  ability  of  miR122  to  suppress  
adenovirus E1A expression following infection of liver-derived Huh7 cells. 
We constructed a chimeric adenovirus (Ad5/3-122) by inserting three perfectly 
complementary  target  elements  for  miR122  in  the  3’UTR  of  the  E1A  mRNA.  In  vitro  
characterization of this virus showed that the E1A expression was specifically 
suppressed in Huh7 cells and the mode of suppression was degradation of the E1A 
mRNA. Although E1A mRNA expression from Ad5/3-122 in Huh7 cells was less than 10 % 
of the E1A mRNA levels of the control virus (Ad5/3-∆24), no significant differences in 
the rate of replication between the viruses were observed. This finding is in agreement 
with previous studies where it has been shown that adenovirus can replicate normally 
in cultured HeLa cells despite greatly reduced levels of E1A protein (Hitt and Graham 
1990). To overcome this problem, we created a virus that had non-specifically reduced 
E1A expression in all cells (Ad5/3K), but replicated similarly to the original virus. A 
miRNA-targeted derivative of Ad5/3K, named Ad5/3K-122, showed liver cell-specific 
suppression of E1A and in contrast to Ad5/3-122, the replication of this virus was also 
dramatically reduced in Huh7 cells (4 orders of magnitude difference in replication 
compared to Ad5/3K). The uniformly reduced E1A expression of Ad5/3K-122 combined 
with the miRNA-mediated suppression of E1A was sufficient to decrease the E1A mRNA 
levels below a threshold at which no viral replication was supported in Huh7 cells. 
However, the requirements for the amount of E1A might be different in transformed 
cell lines than in primary cells. In primary cells, in addition to its transactivation 
properties, E1A is required to inactivate Retinoblastoma (RB) proteins in order to drive 
the  infected  cells  into  the  S-phase  of  cell  cycle  that  is  necessary  for  robust  viral  
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replication (Berk 2005). In transformed cell lines such as HeLa and Huh7, the cell cycle 
regulation is compromised by default and these cells are in a continuously active state 
permitting viral replication to proceed normally despite reduced levels of E1A protein. 
In addition, although Huh7 cells express miR122 to a very high amount, these levels are 
only 8% of the miR122 levels observed in human primary hepatocytes (Chang, Nicolas 
et  al.  2004),  suggesting  that  the  miRNA-mediated  suppression  of  E1A  might  be  even  
more potent in these cells. In a subsequent study using similar approach, Leja et al. 
2010 also combined miRNA-targeting with additional measures in order to decrease 
E1A expression and replication of a miRNA-targeted adenovirus in cultured primary 
hepatocytes and in liver-derived cell line Huh7.5 (Leja, Nilsson et al. 2010). Cawood et 
al. 2009 and 2011 used the miRNA-targeting approach as well to show that luciferase 
expression from a miRNA-targeted E1A-firefly luciferase fusion gene in Ad5 was 
potently suppressed by miR122 in cultured primary hepatocytes and Huh7 cells 
(Cawood, Chen et al. 2009; Cawood, Wong et al. 2011).  
While these studies clearly demonstrated the potency of miRNA-targeting in 
combination with other modifications to de-target the adenovirus from the liver-
derived cells, the replication kinetics of adenoviruses exploiting miRNA-targeting as the 
only modification to the adenoviral genome had not been evaluated in primary 
hepatocytes or in human liver tissue. To this end, we constructed a miRNA-targeted 
derivative  of  wild-type  adenovirus  5  carrying  six  target  elements  for  miR122  in  the  
3’UTR of the E1A mRNA (Ad5T122 in the study II). No other modifications were 
included  in  the  genome  of  this  virus.  With  the  use  of  this  virus,  we  wanted  to  
investigate whether miRNA-targeting alone was sufficient to suppress adenovirus 
replication in human liver. For this purpose, we used an experimental system based on 
ex vivo culturing of precision-cut human liver tissue slices. Considering that human 
adenovirus 5 is normally only capable of an abortive replication in mouse tissues, this 
ex vivo human liver infection model is a superior study system for preclinical evaluation 
of adenoviral induced liver toxicity, and allows the examination of productive 
adenoviral infection in the presence of all the cell types within the context of the 
normal three-dimensional architecture of the human liver. This ex vivo experimental 
system was also used to study the oncolytic potency of Ad5T122 in human tumour 
tissue. Immunohistochemical analyses of Ad5- and Ad5T122-infected liver and tumour 
slices showed clear difference in the intensity and extend of E1A signal between the 
viruses. Ad5-infected liver as well as tumour tissues showed considerable increase in 
E1A signal intensity as the infection proceeded, thus indicating robust replication and 
spread in both tissues. Ad5T122-infected tumour slices showed similar E1A signal 
intensities as Ad5-infected tumour slices, thus indicating that the insertion of miR122 
target elements does not affect the replication of Ad5T122. By contrast, Ad5T122-
infected liver slices did not show any specific signal for E1A indicating a potent and 
miR122-specific suppression of E1A expression. While these experiments 
demonstrated that in normal human liver miR122 can be exploited to suppress E1A 
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expression, the replication of these viruses could not be measured with this approach 
since adenoviral replication can proceed normally even with reduced amounts of the 
E1A protein (as was shown in the study I). To directly examine the productive 
replication of these viruses, the amount of virus in the culture media of Ad5- and 
Ad5T122-infected liver and tumour slices was quantitated at different time points after 
the initial virus administration. The infectious titre of Ad5 in the liver and tissue 
supernatants increased robustly during the 5-day follow-up period confirming that Ad5 
can replicate well in human liver. In contrast, very little Ad5T122 was found in the liver 
tissue supernatants, a direct evidence of the suppressive potential of miR122 target 
elements on adenoviral replication in human liver. In the samples of colorectal cancer 
liver metastasis tissue both viruses replicated to the same extend, thereby confirming 
that the insertion of miR122 target elements had not compromised the replicative 
potential of Ad5T122. Taken together, these data demonstrated that six target 
elements for miR122 in the 3’UTR of E1A mRNA is sufficient without any other 
modifications to prevent productive replication of adenovirus 5 in normal human liver.  
Although human adenovirus 5 does not productively replicate in mouse tissues (Jogler, 
Hoffmann et al. 2006), systemic viral administration is associated with hepatotoxicity 
such as elevated serum levels of the liver enzyme alanine aminotransferase (ALAT). 
Ad5T122 did not induce hepatotoxicity as measured by serum ALAT levels, confirming 
results  obtained  by  Cawood  et  al.  2009  using  very  similar  virus  (Cawood,  Chen  et  al.  
2009). Cawood at al. 2011 showed that miRNA-targeted Ad5-mir122 (four target 
elements for miR122 inserted into the 3’UTR of E1A mRNA) had potent anti-cancer 
efficacy in a Hep2G xenograft mouse model and that the virus was less hepatotoxic 
than  wild-type  Ad5  (Cawood,  Wong  et  al.  2011).   However,  their  treatment  regimen  
included different dosages for Ad5-mir122 and wild-type Ad5 (mice received 10-times 
more Ad5-mir122 than Ad5) complicating the comparison of the oncolytic potency of 
these viruses. We used a lung cancer xenograft model for direct comparison of the 
oncolytic potency of Ad5T122 and Ad5. Ad5T122- and Ad5-infected groups of tumour 
bearing mice received the same amount of virus intratumourally. Both Ad5T122- and 
Ad5-infected groups of mice had significantly reduced tumour growth as compared to 
PBS-treated group of mice. These data conclude that the oncolytic potency of Ad5T122 
was not reduced compared to wild-type Ad5.  
Our data provides a definitive proof of concept and preclinical validation for the use of 
miR122 target elements for reducing the risk of liver toxicity in adenovirus-based 
cancer virotherapy applications. We showed that the insertion of target elements for 
the liver-specific miR122 into the adenovirus 5 genome prevents productive replication 
in liver-derived cells (I) or normal human liver (II). This modification did not 
compromise the replicative capacity of the modified viruses in cells (I, II) or tissues of 
non-hepatic origin (II). Also, the oncolytic potency of Ad5T122 was similar to wild-type 
Ad5 (II).  This miR122-based targeting adds a valuable new safety measure addressing 
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the liver toxicity of therapeutic adenoviruses. Ad5T122 replicated efficiently in liver 
metastatic colorectal cancer emphasizing its potential in the development of better 
systemic treatments for patients with liver metastasized cancer or primary 
hepatocellular carcinoma. In the future clinics, adenoviruses might be “armed” with 
one or more additional gene products that enhance the direct cell killing or immune-
mediated destruction of infected cells via promoting the development of systemic anti-
tumour immunity (Cody and Douglas 2009). To prevent the expression of these 
potentially dangerous genes in hepatocytes could be even more important than 
suppressing the viral  replication itself  (as  has been shown with Ad-HSVtk vectors  see 
(Suzuki, Sakurai et al. 2008)). However, in combination with the targeting of E1A gene, 
these transgenes could also be placed under the control of miR122 for more efficient 
restriction of unwanted expression in hepatocytes. 
 
5.2 MiRNA-mediated	attenuation	of	Semliki	Forest	virus	
neurovirulence	(III)	
In study III we showed that the neuropathogenicity of Semliki Forest virus can be 
selectively attenuated by inserting six perfectly complementary target elements for the 
neuron-specific miRNA miR124 between the non-structural proteins nsp3 and nsp4 in 
the viral genome. In vitro characterization of the miRNA-targeted SFV4 viruses showed 
that the insertion of the target elements did not affect the correct processing of the 
nsp polyprotein as both nsp3 and nsp4 were produced identically to wild-type SFV4. In 
line with our previous results using perfectly complementary target elements in 
adenoviruses (study I and II), the miRNA-mediated suppression of viral proteins was 
shown to occur via endonucleolytic cleavage of viral genomic RNA. In vivo 
characterization of these viruses in BALB/c mice showed that intraperitoneally injected 
SFV4-miRT124 had strongly attenuated neurovirulence but showed similar peripheral 
replication as compared to SFV4-miRT122 control virus. This strongly indicated that the 
reduced neuropathology was not due to attenuated peripheral replication of the SFV4-
miRT124 virus. Interferon-β measurement from the brain tissue following 
intraperitoneal infection correlated well with the viral loads, and consequently, showed 
that whereas both control viruses SFV4 and SFV4-miRT122 induced high levels of 
interferon-β, SFV4-miRT124 did not induce detectable levels of INF-β. These results are 
in line with previous studies where the expression of proinflammatory cytokines in the 
CNS was shown to correlate with the rate of SFV (Tuittila, Nygardas et al. 2004).  
Although SFV4-miRT124 had significantly attenuated neurovirulence compared to the 
SFV4-miRT122 control virus, 1 mouse out of 8 developed severe neurological 
symptoms following intraperitoneal infection. Sequence analysis from the brain tissue 
of this animal revealed that majority of the viruses (89%) contained the original 
sequence introduced between the nsp3 and nsp4 and only a single wild type-like 
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revertant was found. Although these result showed that mutations in the target region 
can occur, the late emergence and low frequency of the escape mutants indicates that 
this might be relatively rare event and unlikely explains the severe outcome of 
infection of this animal.  
Pre-infection of mice with SFV4-miRT124 elicited strong antiviral immunity and 
complete protection against an otherwise lethal challence with a highly neurovirulent 
wild type SFV strain L10. In addition to clearly indicating a robust peripheral replication 
of SFV4-miRT124, this result also suggests that miRNA-targeting could be exploited in 
designing more potent yet safer alphaviral vaccine vectors.  In a recent study, Kamrud 
et al. incorporated target elements for ubiquitously expressed miRNAs into Venezuelan 
equine encephalitis virus (VEEV) replicon helper RNAs that were used for virus-like 
replicon (VRP) production. The rationale behind this approach was to prevent 
expression of helper RNAs and functional recombinants between the replicon and 
helper RNAs in VRP-vaccinated individuals in order to create an additional safety 
measure for VEEV vaccine development (Kamrud, Coffield et al. 2010).  
To further evaluate the neuronal attenuation of SFV4-miRT124, we tested intracranial 
administration of the viruses. Intracranial injection of SFV4 and SFV4-miRT122 viruses 
resulted in widespread infection throughout the brain of the infected mice, whereas 
SFV4-miRT124 infection resulted in a restricted infection pattern and a predominant 
infection of the oligodendrocytes of corpus callosum correlating well with known 
expression patterns of miR124 in the mouse brain (Deo, Yu et al. 2006; Pena, Sohn-Lee 
et al. 2009). The observed infection of the corpus callosum might explain the 
attenuated but still lethal phenotype of SFV4-miRT124 in intracranially infected animals. 
However, similar infection pattern was previously observed with intracranially 
administered SFV strain A7(74) resulting necrotic cell death of the oligodendrocytes of 
corpus callosum but this infection did not lead to death of the infected mice 
(Fazakerley, Cotterill et al. 2006). In light of this report, there is a possibility that a 
hitherto unidentified population of infected non-neuronal cells in the CNS might be 
responsible for the lethal phenotype witnessed in mice intracranially administered with 
SFV4-miRT124. Taken together, intracranial infection with SFV4-miRT124 (even with 
enormous amount of 100 000 PFU of virus) showed efficient neuronal de-targeting, 
confirming the results obtained from the experiments using intraperitoneally 
administered virus. 
Our  results  show  that  the  tissue  tropism  of  a  wild  type  Semliki  Forest  virus  can  be  
selectively modified by the insertion of tissue-specific miRNA target elements into the 
viral genome. By the use of target elements for the neuron-specific miR124, we were 
able to strongly attenuate the neurovirulence of SFV4, thus providing new 
opportunities for studies on SFV4 in preclinical mice models. Indeed, the severe 
neurovirulence of SFV4 has prevented its use as an oncolytic virotherapy agent. The 
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neuronally attenuated SFV4-miRT124 allows overcoming this problem and enables the 
use of SFV4 in preclinical mice cancer models. Furthermore, our findings together with 
the data by Kamrud et  al.  clearly  show that  miRNA-targeting can also be exploited in 
alphavirus vaccine development. 
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6 CONCLUSIONS	
In  this  thesis  we  showed  that  miRNAs  can  be  efficiently  exploited  to  de-target  viral  
replication specifically from tissues accounting for viral pathogenicity. Remarkably, 
miRNA-targeting was successfully used in two very different viruses, one being a 
double-stranded DNA virus and the other being a positive-sense single-stranded RNA 
virus. These results together with a large number of recent publications using different 
RNA- and DNA-viruses are supporting the idea that miRNA-targeting can be used across 
the entire spectrum of viruses. That is particularly important since the most suitable 
and efficient viruses for different applications might yet to be found. Also, given the 
fact that there are a wide variety of differentially expressed, tissue-specific miRNAs 
that could be exploited to de-target viral replication from virtually any given tissue, 
miRNA-targeting approach has a great potential to significantly improve the safety of a 
wide variety of virotherapeutic applications including gene therapy, cancer gene 
therapy and vaccine development.  
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